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The heart rhythm is precisely controlled by the electrical impulse that propagate in the cardiac 
tissue. In single cardiomyocytes, the electrical activity generated by action potentials (AP). 
Cardiac NaV channels (NaV1.5) carry a large influx of Na
+ that mediates the initiation and 
propagation of the AP in both atria and ventricles. Disruption of NaV1.5 function by genetic 
variants or external factors can result in deadly arrhythmias, such as long QT syndrome and 
Brugada syndrome. Thus, NaV channels are import therapeutic targets. The class I 
antiarrhythmics are the modulators of the NaV channels. Although they have been used clinically 
for over 100 years, detailed mechanisms of their action are not well understood. The NaV channel 
co-assembles with many regulatory and accessory proteins to form a macromolecular complex 
that tailor channel function to different cells. The complicated multi-molecular interactions add 
another level of complexity in dissecting the drug mechanisms. 
xi 
 
The pore-forming NaV1.5 α-subunit contains four domains (DI-DIV), each with a voltage 
sensing domain (VSD). The voltage clamp fluorometry (VCF) method probes the conformational 
changes of each VSD by attaching a fluorophore on it. Here, we utilized VCF to measure how 
the accessary β-subunits and Class Ib antiarrhythmics affect the conformational dynamics of the 
NaV1.5.  
We found that the non-covalently linked β1 and β3 subunits regulate channel gating by altering 
the DIII and DIV-VSD dynamics. Moreover, results from multiple experiments provided 
compelling evidence that β1 and β3 bind proximally to the DIII-VSD.  
The DIII-VSD also plays an important role in channel’s interaction with Class Ib 
antiarrhythmics, such as lidocaine, ranolazine and mexiletine. Recent clinical studies showed that 
mexiletine is effective in treating patients with LQT3 syndrome. However, the patient response 
is variable, depending on the genetic mutation in NaV 1.5. We showed that mexiletine altered the 
conformation of the DIII-VSD, which is the same VSD that many tested LQT3 mutations affect. 
Analysis of 15 LQT3 variants showed a strong correlation between the activation of the DIII-
VSD and the strength of the inhibition of the channel by mexiletine. Based on this improved 
molecular-level understanding, we generated a systems-based model that successfully predicted 
the response of 7 out of 8 patients to mexiletine in a blinded, retrospective clinical trial. The new 
model can be used to personalize treatment for LQT3 patients, and improving therapeutic 
decision making. 
As the non-covalently linked β subunits and the Class Ib antiarrhythmics both interact with the 
same part of the NaV channel. We further investigated how β expression affects the Class Ib drug 
effectiveness. We found that β1 differentially modulates lidocaine and ranolazine blockade of 
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NaV1.5. The molecular mechanism underlying this phenomenon is due to altered drug interaction 
with the DIII-VSD. In human hearts, β1 expresses at levels that are 3-fold higher in the atria 
compared to ventricles. Thus, this molecular difference can be targeted to develop chamber 
specific antiarrhythmic therapies. 
In conclusion, we demonstrated the essential role of the DIII-VSD dynamics in modulating NaV 
channel response to the Class Ib antiarrhythmics. This molecular interaction is regulated by the 
accessary β subunits. We hope to apply this mechanistic insight to improve current 
antiarrhythmic therapeutic approaches.   
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Chapter 1 
Introduction  
 
1.1 NaV1.5 macromolecular signaling complex 
The heart is an electrical and mechanical organ that pumps blood to the circulation system to 
maintain constant blood flow of the body. The activity of the heart is delicately controlled by the 
electrical signal that travels through the tissue. The electrical rhythm is first initiated by a group 
of cells called pacemaker cells in the SA node, which is then conducted through cells known as 
cardiomyocytes in the atrium and ventricle to cause contraction of the heart (Zipes & Jalife, 
2013). In individual cardiomyocyte, the electrical activity is reflected as action potentials (AP), 
as the cell membrane potential depolarizes and repolarizes. The AP is controlled by varies well-
balanced ionic currents through the membrane, which are carried by the ion channels (Nerbonne 
& Kass, 2005). When electrical impulse reaches the cardiomyocyte, it depolarizes the membrane 
to reach the threshold for opening the NaV channels. Then, NaV channels rapidly open, carrying a 
large influx of Na+ ions that greatly depolarizes the membrane (Bertil Hille, 2001). Thus, NaV 
channel controls the upstroke of AP and propagation of electrical signal in both atria and 
ventricles.  
Since the NaV channel are essential for regulating cardiac excitability, any disturbance of channel 
function, either by inherited genetic mutations or external factors can lead to serious diseases. 
Cardiac arrhythmia is a pathological condition where the heart loses its regular rhythm and stops 
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pumping blood efficiently. NaV channel dysfunction can cause arrhythmias such as Long QT 
syndrome (Schwartz et al., 2001), Brugada syndrome (Brugada & Brugada, 1992) and atrial 
fibrillation (Morten S Olesen, Nielsen, Haunsø, & Svendsen, 2014). All those types of 
arrhythmias are extremely dangerous, as they can result in sudden cardiac death if not terminated 
in time. Hence, NaV channel are important therapeutic targets. 
1.1.1 Voltage-gated NaV Channel Structure and Gating 
The eukaryotic NaV channels all share common structures. They are formed by four homologous 
domains connected by intracellular linkers. Each domain consists of six transmembrane 
segments (S1-S6) (Ganetzky, Robertson, Wilson, Trudeau, & Titus, 1999; Gellens et al., 1992b; 
Itoh et al., 1998; Qin, Yagel, Momplaisir, Codd, & D’Andrea, 2002). The fourth segment (S4) 
has several positive charged residues (Arginine and Lysine) that drive the S4 segment up cell 
membrane depolarization. Therefore, the S1-S4 segments are called voltage sensing domain 
(VSD). The S5-S6 segments of all four domains form the pore, where Na+ ions pass through. 
When membrane depolarizes, the VSDs changes their conformations, which are coupled to the 
pore through the S4-S5 linker and other mechanisms to make the pore open (Aggarwal & 
MacKinnon, 1996; Bezanilla, 2008; Liman, Hess, Weaver, & Koren, 1991; Seoh, Sigg, 
Papazian, & Bezanilla, 1996). Their structure is domain-swapped, which means that VSD of one 
domain is adjacent to the pore of the other domain. This unique assembly mediate the complex 
couplings of each parts of the channel.  
The intracellular linkers and domains also paly an essential role in channels gating. In particular, 
the DIII-DIV linker contains the IFM motif that is known as the inactivation gate (West et al., 
1992). Quickly after channel opens, the inactivation gate moves to interact proximal to the pore. 
This action occludes the Na+ flux and cause the channel to inactivate. Inactivation almost 
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diminishes all the INa, except a very small portion (~1-2%), which is called the late or sustained 
INa  (Maltsev, Kyle, & Undrovinas, 2009a). Previous studies suggest that an increase in late INa 
by signaling molecules, mutations, and drugs can be very arrhythmogenic, because it competes 
with the repolarizing Ik that results in prolongation of the AP (Zipes & Jalife, 2013).  
Unlike potassium channel, which is a tetramer formed by four identical subunits, NaV channel 
has an asymmetrical structure, because it is formed by four different domains. Each domain 
contributes to channel gating distinctively. The DIV-VSD has been shown to associate with 
channel inactivation, and other three VSDs are more related to channel activation (Albert Cha, 
Peter C., Alfred L., Esther, & Francisco, 1999). However, more recent literatures suggest that 
DIII-VSD plays multiple roles in regulating channel activation, inactivation and recovery from 
inactivation (Hsu et al., 2017a).  
1.1.2 Accessary β Subunits Regulate NaV Channel Function 
NaV channels form macromolecular signaling complexes in cardiomyocytes (Abriel, 2010), 
whose parts work in concert to regulate channel function. The Nav channel β subunit members of 
this complex have been shown to regulate cell adhesion (Isom, Ragsdale, et al., 1995b; Jyoti 
Dhar Malhotra, Kazen-Gillespie, Hortsch, & Isom, 2000a; Yu et al., 2003) and signaling in 
addition to affecting NaV channel density (Calhoun & Isom, 2014), gating kinetics (Fahmi et al., 
2001; H. Watanabe et al., 2009), and pharmacology (Lenkowski, Shah, Dinn, Lee, & Patel, 
2003; Uebachs et al., 2010).  
The Nav channel β1 and β2 subunits were first to be identified and were purified together with 
the pore-forming NaV α subunit, from the rat brain (Hartshorne & Catterall, 1984; Messner & 
Catterall, 1985). Subsequently, three additional members of the family, β1b (Kazen-Gillespie et 
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al., 2000), β3 (Morgan et al., 2000b) and β4 (Yu et al., 2003) were identified based on homology. 
β2 and β4 form covalent disulfide bonds with the α subunit (Isom, Ragsdale, et al., 1995a), while 
β1 and β3 interact non-covalently (Isom, Scheuer, et al., 1995; Morgan et al., 2000b). With the 
exception of the β1b splice variant (Patino et al., 2011), the β subunits comprise a single 
transmembrane-spanning domain that is tethered to an extracellular Immunoglobulin (Ig) loop 
and a cytoplasmic C-terminus (Calhoun & Isom, 2014). Very recently, the covalently bound β2 
and β4 were crystallized (Das, Gilchrist, Bosmans, & Van Petegem, 2016; Gilchrist, Das, Van 
Petegem, & Bosmans, 2013), and a crucial disulfide bond formed by 55Cys in β2 and 910Cys in 
the DII pore loop was localizing β2 to the DII pore domain (Das et al., 2016). However, 910Cys 
is not present in Nav1.5, and instead the homologous position is Leu.  
The β subunits are widely expressed in many tissues, including the central and peripheral 
nervous system, the heart, and skeletal muscle (Calhoun & Isom, 2014). Intriguingly, even in the 
same organ, β subunit localization can differ (Calhoun & Isom, 2014; Fahmi et al., 2001; Yuan et 
al., 2014). For example, the β1 and β3 subunits have been shown to differentially express in the 
atria and ventricles (Fahmi et al., 2001; H. Watanabe et al., 2009; Yuan et al., 2014), suggesting 
that they may specifically tailor NaV channel function according to cell type. The physiological 
role of the β-subunits is highlighted by the recent linkage between β subunit mutations and 
epilepsy (Calhoun & Isom, 2014), Dravet syndrome (Calhoun & Isom, 2014), and cardiac 
arrhythmias, including Brugada Syndrome (Hu et al., 2012; Hiroshi Watanabe et al., 2008), Long 
QT Syndrome (Medeiros-Domingo et al., 2007; Riuró et al., 2014), Sudden Infant Death 
Syndrome (Calhoun & Isom, 2014) and atrial fibrillation (Li et al., 2013; M S Olesen et al., 
2011) (AF). Further, since β subunits can co-assemble with more than one type of Nav channel, 
mutations in β subunits can lead to multi-organ diseases. For example, the β1 subunit R85H 
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variant has been linked to both epilepsy (Xu et al., 2007) and atrial fibrillation (AF) (H. 
Watanabe et al., 2009).  These myriad findings suggest that significant insight into the molecular 
basis of the many pathologies and drug interactions could be gained via a deeper understanding 
of the mechanisms of NaV channel regulation by the β subunits. 
1.2  Voltage clamp fluorometry 
1.2.1. Introduction to voltage-clamp fluorometry 
Despite much progress in understanding how channels sense voltage and selectively allow ions 
to cross into and out of the cell, the conformational changes that determine AP dynamics are not 
well-defined. A method known as voltage-clamp fluorometry (VCF) allows simultaneous 
observation of changes in channel conformation and ionic current kinetics, and very recently, 
VCF protocols have been established for major cardiac ionic currents including the cardiac Na+ 
current (INa), the L-type Ca2+ current (ICa,L), the rapid and slow components of the delayed 
rectifier K+ currents (IKr and IKs), and the Na+/K+ ATPase (INaK).  
1.2.2 The VCF protocol 
VCF was first used to observe the prototypical Shaker K+ channel VSD with a fluorophore 
tethered to the S4 segment (Mannuzzu, Moronne, & Isacoff, 1996). As the environment 
surrounding the S4 was altered by VSD movement in response to changes in membrane 
potential, the fluorescence emission from the tethered fluorescent molecule was also altered (Fig. 
1.1A). Thus, the change in fluorescence emission could be used to observe the voltage-dependent 
kinetics of the VSD.  
Fluorophore tethering for VCF is typically accomplished by introducing a cysteine residue into 
the area of interest and labeling it with a thiol-reactive fluorophore. Native cysteines are often 
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removed in order increase the specificity of labeling and reduce background fluorescence 
(Gandhi & Olcese, 2008). To track VSD conformation, the fluorophore is usually conjugated to a 
cysteine into the S3–S4 linker (Fig. 1A). 
 
The fluorescence signal created by the change in channel conformation is usually quite small, so 
large numbers of channels must be expressed to observe a useful signal. The Xenopus oocyte is 
often used as it is well-known to express large numbers of channels from mRNA that is injected 
into the cytoplasm. The oocyte also has a dark pigmented layer directly beneath the membrane of 
the animal pole, which eliminates most of auto-fluorescence from cell, allowing for resolvable 
fluorescence signals (Gandhi & Olcese, 2008). In mammalian cells, the whole-cell patch clamp 
configuration has been combined with semiconfocal epifluorescence microscopy to observe 
Shaker K+ channel conformations (Blunck, Starace, Correa, & Bezanilla, 2004). However, 
Figure 2.1 A) Kv channel VCF construct under resting 
(transparent) and activated (solid) states. The pink dot 
represents the engineered cysteine residue and yellow star 
denotes the tethered fluorophore. The movement of the S4 
segment causes fluorophore displacement. As a result of 
quenching by surrounding residues, and changes in 
fluorophore environment, fluorescence emission is altered. 
B) Above: mRNA encoding VCF channel constructs are 
injected into Xenopus oocytes. Channels express at high 
levels after several days. Channels are then labeled with a 
fluorophore, which conjugates to the introduced cysteine 
residues. Below: An example highlighting cut-open oocyte 
recording, which allows resolution of fast kinetics by 
clamping a small membrane patch. The upper chamber 
filled with external solution is clamped to the command 
voltages, while the bottom channel filled with internal 
solution is connected to ground. Membrane currents are 
measured using the electrode filled with 3 M KCl. 
Fluorescence emission is separated from excitation light by 
a dichroic mirror and filtered by the emission filter. 
Finally, it is collected with a photodiode that is connected 
to a low noise current amplifier. 
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cardiac channels have not been successfully studied using this method. One challenge to 
studying these channels is much lower channel density, in comparison to Shaker. 
In the oocyte protocol, channels typically express at high levels 3–7 days after RNA injection, 
and they are subsequently labeled with a thiol-reactive fluorophore, which binds to the 
introduced cysteine (Fig 1.1B). Then, ionic currents and fluorescence emission can be recorded 
using the two-electrode or cut-open oocyte Vaseline gap (COVG) voltage-clamp configuration. 
The COVG configuration provides faster clamping and lower noise, and is commonly applied to 
observe Ca2+ and Na+ channel currents whose fast kinetics are physiologically pertinent (Fig. 
1B)(Antonios Pantazis & Olcese, 2013; Siefani & Bezanilla, 1998). Changes in fluorescence 
emission are tracked simultaneously with a photodiode (Albert Cha et al., 1999; Rudokas, Varga, 
Schubert, Asaro, & Silva, 2014) that is coupled to a patch clamp amplifier or by a 
photomultiplier tube (Mannuzzu et al., 1996). 
There are multiple physical mechanisms that could underlie the observed changes in 
fluorescence. First, displacement of the fluorophore upon VSD activation could enable the 
fluorophore to move from a lipid environment to the extracellular solution, resulting in 
fluorescence quenching and a right shift in the emission spectrum (Blunck, 2015). Second, 
changes in fluorescence emission can also be caused by photo-induced electron transfer, a 
quenching mechanism where electrons are transferred between two molecules via a non-radiative 
path could reduce fluorescence emission as the fluorophore approaches a quenching molecule 
(Doose, Neuweiler, & Sauer, 2005, 2009; Marmé, Knemeyer, Sauer, & Wolfrum, 2003; Vaiana 
et al., 2003). This transfer typically occurs within the van der Waals radius (10 Å), and the 
amount of quenching varies between amino acids. Tryptophan and tyrosine are usually the most 
potent quenchers (Chen, Ahsan, Santiago-Berrios, Abruña, & Webb, 2010). In support of the 
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latter mechanism, VCF in Shaker K+ channels showed no shift in the spectrum of fluorescence 
emission, implying that a change in solvent environment is not responsible for the fluorescence 
signal in these experiments (A Cha, Snyder, Selvin, & Bezanilla, 1999). As it is currently not 
possible to reliably predict how a fluorophore at a particular position will be quenched, 
development of VCF DNA constructs often requires cysteine scanning of multiple positions for 
fluorophore labeling. If multiple labeling sites produce usable signals, the labeled cysteine that 
minimally perturbs the channel function is typically chosen. Further, the location of the optimal 
labeling site can depend on the fluorophore's properties, including its solubility, the length of the 
carbon chain that connects the fluorophore to the thio-reactive group, and its charge content 
(Hughes, Rawle, & Boxer, 2014).  
1.2.2.  Overview of the Cardiac sodium channel NaV1.5 VCF Results 
VCF was first applied to skeletal muscle NaV channels (NaV1.4) and has been used to probe VSD 
interaction with inactivation (Albert Cha et al., 1999; Silva & Goldstein, 2013b), local 
anesthetics (Arcisio-Miranda, Muroi, Chowdhury, & Chanda, 2010b; Muroi & Chanda, 2009a), 
2009), and toxins (Campos, Chanda, Beirão, & Bezanilla, 2007, 2008). To probe similar 
phenomena in the cardiac channel, we recently developed VCF protocols to track each of the 
VSDs of NaV1.5. Out of 16 positions attempted, we observed robust signals with DI-V215C, 
DII-S805C, DIII-M1296C, and DIV-S1618C (Varga et al., 2015). Each of the VSDs displayed 
unique voltage-dependent kinetics. The DI, DII, and DIII VSDs each activated much more 
rapidly than DIV (Fig 1.2). Deactivation of DI and DII were also rapid, while DIII- and DIV-
VSD deactivation was markedly slower than activation (Fig 1.2). To quantify voltage 
dependence, VSD activation is typically measured by recording peak fluorescence after stepping 
to various depolarizing potentials, the fluorescence-voltage (F–V) curve. We observed that the 
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V1/2 of the F–V curves for each NaV1.5 VSD is more negative than channel activation (G-V 
curve) (Fig 1.2), suggesting that activation of the VSDs occurs prior to pore opening. The DII-
VSD stands out, by completing its activation at higher potentials than the channel conductance, 
which could suggest that the DII-VSD is a facilitator channel activation whose transition is not 
absolutely required to open the channel pore (Fig 1.2).  
 
Figure 1.2.  Representative current and fluorescence traces of four Nav1.5 VCF constructs, describing four VSDs, 
in response to voltage pulses from −100 mV, a 50ms step to −120 mV preceded by 20ms-long test pulses to −150, 
−90, −30, +30 mV. These steps were then followed by a 50ms step to −120 mV before returning to the holding 
potential. G-V curve (black circles), SSI (black squares), and the corresponding fluorescence voltage relationship F–
V curve (color circles and squares, respectively). 
VSD activation can also be observed during protocols that measure channel inactivation. A 
typical steady-state inactivation protocol measures peak Na+ current during a test pulse that 
follows 200 ms long inactivation-inducing pulses. Significant inactivation occurs at negative 
potentials during these pulses, before the channel opens. Thus, the protocol is primarily 
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measuring closed-state inactivation. Tracking DIV-VSD conformation during the steady-state 
inactivation protocol reveals a striking correlation between DIV-VSD activation and closed-state 
inactivation (Fig 1.2), similar to previous findings in Nav1.4, where DIV-VSD activation was 
found to be the rate limiting step of channel inactivation (Capes, Goldschen-Ohm, Arcisio-
Miranda, Bezanilla, & Chanda, 2013).  
1.2.2.  Future applications of the VCF technique 
In later chapters, we showed using these NaV1.5 VCF constructs to reveal details of α subunit 
interaction with accessory β subunits, the molecular pathology of inherited mutations, how class 
I anti-arrhythmic drugs interact with the VSDs, and mechanisms whereby post-translational 
modifications control channel gating. VCF data will also be tremendously useful for creating 
computational AP models. For example, traditional, Hodgkin–Huxley type, models imply that 
each of the channel “gates” must be open before the channel is able to conduct ionic current. 
This requirement has persisted to date, even in modern Markov type models that simulate 
complex drug interactions (Moreno et al., 2011). In contrast, the above DII-VSD results imply 
that the NaV1.5 pore may open even if the DII-VSD gate remains in the resting conformation, 
which would require an allosteric model. Moreover, the VCF data also provides a molecular 
connection, revealing specific channel domains that are responsible for the transitions that are 
represented in the model. Thus, by parameterizing computational models with VCF data, it will 
be possible to explicitly represent experimentally measured channel conformational dynamics 
within models of the AP. Such models will be able to connect the molecular dynamics of NaV1.5 
channel gating, drug interaction and post-translational modification to the cell and tissue 
dynamics. 
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1.3: Antiarrhythmic drug therapy 
Antiarrhythmic therapy was first used in clinical practice over 100 years ago (Zimetbaum, 2012). 
The concept of antiarrhythmic is to modulate one or more ion channels functions or signaling 
pathways in cardiomyocytes, which counterbalance the disturbance of regular rhythm due to 
arrhythmias. Normally, the electrical impulse generates in the SA node, and travels down the 
atrium and AV node, then quickly spreads through the purkinje fibers to excite the whole 
ventricle, which causes a synchronized contraction (Zipes & Jalife, 2013). The electrical signal 
only propagates unidirectional because the myocytes that just got excited cannot fire another 
action potential immediately, a phenomenon called refractory (Burton & Cobbe, 2001). The time 
that a myocyte remains in refractoriness is defined as effective refractory period (ERP). In some 
cases of arrhythmia, the electrical signal fails to travel down the normal pathway, rather it circles 
back to the tissue that has been already excited, a phenomenon termed reentry, which will result 
in unsynchronized contractions that are not able to pump blood efficiently. The reentry can 
happen due to numerous reasons. Some common causes are shortening of ERP, prolongation and 
shortening of action potential duration (APD), or slowing of conduction velocity (CV). Altering 
the INa alone can result in changes in all three parameters, as the channel recovery from 
inactivation determines the ERP, late INa affects the APD, and peak INa modulates the CV. Given 
the intricacy of how ionic currents influence reentry circuit, we can imagine that antiarrhythmic 
requires precise control of currents.  
The lack of understanding in antiarrhythmic mechanisms resulted in catastrophic failures in the 
clinical trials. One example is the cardiac arrhythmia suppression trial (CAST) trial of Class Ic 
drug flecainide (Greene et al., 1992), on patients post myocardium infarction. The trial showed 
that patients under flecainide therapy showed lower survival rate compared to patients under 
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placebo (Echt et al., 1991). This depressing outcome is because flecainide blocks the peak INa, 
which resulted in great slowing in the CV that was arrhythmogenic. This examples shows that 
Antiarrhythmic therapy can have adverse effects if not used properly.  
1.3.1 Classification of Antiarrhythmia Drugs  
The most commonly used classification for antiarrhythmic agents are Vaughan Williams and 
Singh's classification, which categorizes drugs based on their effects on the AP morphology. It 
separates antiarrhythmics into four classes, NaV channel blockers (Class I), beta adrenergic 
pathway blocker (Class II), KV channel blockers (Class III), and CaV channel blockers (Class IV) 
(Vaughan Williams, 1970). Each class is further separated into subclasses. For example, the 
Class I agents have subclasses of Ia, Ib, and Ic, where Ia drugs slows down upstroke and 
prolongs duration of AP, Ib drugs shorten the AP duration, and Ic drugs delay upstroke without 
affecting the AP duration (Vaughan Williams, 1970).  
The Vaughan Williams and Singh’s classification is still being used in clinics. However, this 
classification is greatly limited by the fact that it was based on outcomes, but not mechanisms. 
To prevent the adverse effects of antiarrhythmics, it is essential to develop mechanism-based 
therapy for different diseases, or even different patients.  
1.3.2 Class Ib Antiarrhythmic  
Class Ib agents, such as lidocaine, are also used as local anesthetics to treat pain. As local 
anesthetics, they have been extensively studies in the past. Over 40 years ago, Bertil Hille 
proposed that lidocaine has two ways to enter the channel pore, the hydrophobic and hydrophilic 
pathways (B Hille, 1977). The binding actions were further described by the modulated receptor 
theory (Hondeghem & Katzung, 1984). It emphasized that lidocaine binding to the channel pore 
stabilized the channel inactivation, and an inactivated channel has higher affinity for lidocaine. 
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This theory was able to explain the two different types of blocks induced by lidocaine, tonic 
block (TB) and use-dependent block (UDB). However, as we gained more knowledge of the 
NaV channel structure, it is clear that the modulated receptor is a much simplified view of Class 
Ib drug action. The detailed allosteric changes in channel conformation needs to be incorporated 
into the model.   
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Chapter 2  
Mechanisms of noncovalent β subunit 
regulation of NaV channel gating 
 
Large portions of this chapter is adapted from 
Zhu, W., Voelker, T. L., Varga, Z., Schubert, A. R., Nerbonne, J. M., & Silva, J. R. (2017). 
Mechanisms of noncovalent β subunit regulation of NaV channel gating. The Journal of General 
Physiology. http://doi.org/10.1085/jgp.201711802 
2.1 Summary  
Voltage-gated Na+ (NaV) channels comprise a macromolecular complex whose components 
tailor channel function. Key components are the non-covalently bound β1 and β3 subunits that 
regulate channel gating, expression, and pharmacology. Here we probe the molecular basis of 
this regulation by applying voltage-clamp fluorometry to measure how the β-subunits affect the 
conformational dynamics of the cardiac NaV channel (NaV1.5) voltage-sensing domains 
(VSDs). The pore-forming NaV1.5 α-subunit contains four domains (DI-DIV), each with a VSD. 
Our results show that β1 regulates NaV1.5 by modulating the DIV-VSD, whereas β3 alters 
channel kinetics mainly through DIII-VSD interaction.  Introduction of a quenching tryptophan 
into the extracellular region of the β3 transmembrane segment inverted the DIII-VSD 
fluorescence.  Additionally, a fluorophore tethered to β3 at the same position produced voltage-
dependent fluorescence dynamics strongly resembling those of the DIII-VSD.  Together these 
results provide compelling evidence that β3 binds proximally to the DIII-VSD.  Molecular-level 
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differences in β1 and β3 interaction with the α subunit lead to distinct activation and inactivation 
recovery kinetics, significantly affecting NaV channel regulation of cell excitability.   
2.2 Introduction  
In electrically excitable organs, such as the heart, brain, and skeletal muscle, voltage-gated Na+ 
(NaV) channels cause the initiation and propagation of action potentials by conducting a large 
and rapid inward Na+ flux. Within the cells of these tissues, NaV channels form macromolecular 
signaling complexes (Abriel, 2010), whose parts work in concert to regulate channel function. 
The Nav β subunit members of this complex have been shown to regulate cell adhesion 
(Malhotra et al. 2000;  Isom et al. 1995; Yu et al. 2003) and signaling, in addition to affecting 
channel density (Calhoun & Isom, 2014), gating kinetics (Calhoun & Isom, 2014; Fahmi et al., 
2001; Hiroshi Watanabe et al., 2009), and pharmacology (Lenkowski et al., 2003; Uebachs et al., 
2010). However, the mechanisms whereby the β subunits interact with the NaV channel α-subunit 
to exert their influence on gating remain undiscovered. 
Five types of Nav β subunits have been identified, β1, β2, β3, β4, and β1b (Hartshorne & 
Catterall, 1984; Kazen-Gillespie et al., 2000; Messner & Catterall, 1985; Morgan et al., 2000b; 
Yu et al., 2003). β2 and β4 form covalent disulfide bonds with the α subunit (Isom et al. 1995; 
Yu et al. 2003), while β1 and β3 interact non-covalently (Isom et al. 1992a; Morgan et al. 
2000a). With the exception of the β1b splice variant (Patino et al., 2011), the β subunits comprise 
a single transmembrane domain that is tethered to an extracellular Immunoglobulin (Ig) loop and 
a cytoplasmic C-terminus (Calhoun & Isom, 2014). Very recently, the covalently bound β2 and 
β4 were crystallized (Das et al., 2016; Gilchrist et al., 2013), and a crucial disulfide bond formed 
by 55Cys in β2 and 910Cys in the DII pore loop was identified (Das et al., 2016). However, 910Cys 
is not present in Nav1.5, and instead the homologous position is 
868Leu.  
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The β subunits are widely expressed in many tissues, including the central and peripheral 
nervous system, the heart, and skeletal muscle (Calhoun & Isom, 2014). Despite the sequence 
homology between non-covalently associated β1 and β3 subunits, their expression profile across 
organs differs. For instance, β1 is highly expressed in skeletal muscles, but not β3 (The Human 
Protein Atlas).  Intriguingly, even in the same organ, β subunit localization can differ (Calhoun 
& Isom, 2014; Fahmi et al., 2001; Yuan et al., 2014). For example, the β1 and β3 subunits have 
been shown to differentially express in the atria and ventricles (Fahmi et al., 2001; Hiroshi 
Watanabe et al., 2009; Yuan et al., 2014), suggesting that they may specifically tailor NaV 
channel function according to cell type. Moreover, β1 and β3 also have a varied temporal 
expression profile during heart development. β1 expression was shown to increase (Domínguez 
et al., 2005), whereas β3 was shown to decrease through embryonic development (Okata et al., 
2016). The dynamic expression patterns of β1 and β3 suggest that these two subunits play 
distinct roles in regulation of NaV channel function and the action potential.  
The pore-forming NaV channel α-subunit is composed of four homologous domains (DI-DIV) 
connected by cytoplasmic linkers (Gellens et al., 1992a). Each domain is formed by six α-helical 
transmembrane segments (S1-S6). The fourth segments (S4) contain multiple positively charged 
residues that move across the membrane in response to changes in membrane potential. S4, 
together with S1-S3, form the voltage sensing domains (VSDs) and are coupled to the S5 and S6, 
which form the channel pore. Upon membrane depolarization, the S4 segments within the VSDs 
of DI-DIII are propelled outward to open the channel within a millisecond, known as channel 
activation (Chanda & Bezanilla, 2002). Shortly thereafter, channels rapidly close, a process 
termed ‘fast inactivation’ that is mediated by the intracellular DIII-DIV linker and the DIV-VSD 
(West et al., 1992). Both activation and inactivation gating have been previously shown to be 
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modulated by the β1 and β3 subunits (Calhoun & Isom, 2014; Fahmi et al., 2001; Morgan et al., 
2000a; Hiroshi Watanabe et al., 2009).  
Much mechanistic insight into NaV channel gating has been recently provided by applying the 
voltage clamp fluorometry (VCF) protocol, used to fluorescently track VSD conformation and 
correlate VSD kinetics with ionic current gating.  For many years, this protocol has been applied 
to study the skeletal muscle isoform NaV1.4, and it has provided great insight into the VSD roles 
in determining activation and inactivation gating kinetics (Cha et al., 1999; Chanda & Bezanilla, 
2002; Silva & Goldstein, 2013a, 2013b), the mechanisms of local anesthetic regulation of the 
VSDs (Arcisio-Miranda et al., 2010; Muroi & Chanda, 2009), and details of how toxins 
pathologically affect VSD activation (Campos et al., 2007, 2008). We have recently broadened 
this approach by developing voltage clamp fluorometry (VCF) constructs to track VSD 
conformations of all four domains in the cardiac paralog, Nav1.5 (Varga et al., 2015; Zhu et al., 
2016), whose ionic current modulation by β subunit in oocytes mirrors the mammalian cell 
phenotype.  
We hypothesized that the non-covalently bound β1 and β3 subunits modulate NaV1.5 ionic 
current kinetics by altering the activation of one or more VSDs. In this study, we test this 
hypothesis by applying VCF to observe the β subunit effects on the VSD of each NaV1.5 
domains.  
2.3 Results  
β1 regulates channel inactivation by altering voltage-dependent DIV-VSD transitions  
We co-expressed the human β1 subunit with the pore-forming hNav1.5 α subunit in Xenopus 
oocytes by co-injecting β1 and α subunit mRNA at a molar ratio of 3:1. β1 co-expression had no  
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Figure 2.1 Nav β1 regulates Nav1.5 inactivation by altering DIV-VSD activation. Nav1.5 ionic currents were 
measured using the cut-open voltage clamp technique to resolve fast Na+ channel kinetics. Changes in site-specific 
fluorescence of Nav1.5 are reported by four VCF constructs (V215C, S805C, M1296C, and S1618C) after 
conjugating to MTS-TAMRA (Varga et al., 2015). The mean ±SEM is reported for groups of 3-8 cells. The error 
bars represent the SEMs. Some error bars are not visible due to small SEMs.  
a) Topology of Nav1.5 and Nav β1 subunits on plasma membrane. b) Voltage-dependence of activation (G-V) and 
steady state inactivation (SSI) for WT Nav1.5 with β1 (α+β1, square), or without β1 (α, circle). c) Representative 
current traces of WT channel with β1 (black), or without β1 (grey) in response to depolarizing pulse to 0mV from -
120mV. d) Time dependence of fraction of current recovered for channels with β1 (α+β1, square), or without β1 (α, 
circle). (f-i) Left panel, Voltage dependence of steady-state fluorescence (F-V curve) from all four domains f) DI-
S216C, g) DII-S805C h) DIII-M1296C, and i) DIV-S1618C co-expressed with (α+β1, squares), or without β1 
subunit (α, circles).  
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significant effect on the voltage-dependence of WT channel activation, as shown by the 
conductance-voltage (G-V) curve (Fig 2.1b), but caused a depolarizing shift in the channel 
steady-state inactivation (SSI) curve, compared to WT alone (ΔV1/2=12.2 ±1.4 mV, p=0.02) (Fig 
2.1b).  The right-shifted SSI curve implies that more channels are available to open at higher 
potentials.  Moreover, β1 further increased channel opening by accelerating channel recovery 
from inactivation (Fig 2.1d). To ensure that the changes in the β1 regulation mechanism that we 
observed were consistent across different expression systems, we also used identical protocols to 
assess β1 effects on Nav1.5 currents in HEK 293T cells, and observed similar behavior. The β1-
induced depolarization of SSI we observed is also consistent with previous results in HEK 293 
and HEK 293T cells (Malhotra et al. 2001; An et al. 1998; Maltsev et al., 2009).  
We investigated how β1 modulates inactivation by first measuring gating currents, which reflect 
charge translocation of all four VSDs. To be able to measure the gating current for the NaV1.5 
channel, we used the WT-LFS construct, which contains C373Y mutation that increases channel 
sensitivity to TTX, and the Y1977A mutation that prevents ubiquitination of the channels to 
increase expression (Varga et al., 2015). Comparison between the gating charge voltage-
dependence (Q-V) of WT-LFS channels co-expressed with and without the β1 subunit (Fig 2.1e) 
revealed that β1 caused a depolarizing shift in the Q-V curve at negative potentials, resulting a 
steeper Q-V relationship (Δk=-10.1±4.2 mV, p=0.04). This result suggests that in the presence of 
the β1 subunit, one or more of the VSDs requires higher potentials to activate. To identify which 
VSD(s) was affected, NaV1.5 VCF constructs were co-expressed with the β1 subunit.  We have 
previously shown that MTS-TAMRA-labeled Nav1.5 channels activate and inactivate similarly 
to WT channels (Varga et al., 2015).  Co-expression of the β1 subunit with the VCF constructs 
caused a shift in the SSI curves that is similar to the shift caused by β1 in WT channels. The 
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voltage-dependence of activation of each VSD can be described by plotting steady-state 
fluorescence against voltage (F-V curve). In comparison to α alone, the β1 subunit did not 
significantly alter the DI, DII, or DIII F-V curves (Fig 2.1f-h), but induced a strong depolarizing 
shift in the DIV F-V curve (ΔV1/2=31.3±1.7mV, p=0.02) (Fig 2.1i). Thus, in the presence of the 
β1 subunit, the DIV-VSD requires higher potentials to accomplish its activation transition, 
consistent with the gating charge shift (Fig 2.1e).  
Previously, DIV-VSD activation was shown to be more closely linked to NaV channel 
inactivation, than activation (Capes, Goldschen-Ohm et al., 2013; Cha et al., 1999). Specifically, 
the DIV-VSD was observed to be immobilized by fast inactivation (Cha et al., 1999), and DIV-
VSD activation was shown to be the rate-limiting for fast inactivation (Capes et al., 2013). 
Hence, changes in the voltage dependence of DIV-VSD activation or DIV-VSD kinetics would 
be expected to cause correlated changes in channel steady-state inactivation (SSI) or inactivation 
kinetics. Notably, DIV-VSD deactivation kinetics are also faster with β1 (t100%-10% =4.5±0.6ms at 
-160mV after 0mV pulse), compared to α alone (t100%-10% =13.2±0.4ms at -160mV after 0mV 
pulse, p=0.0003).  Thus, our results imply that the β1 subunit regulates inactivation by altering 
DIV-VSD transitions. This mechanism is consistent with previous studies suggesting that β1 
binds to the C-terminus of Nav1.1 (Spampanato et al., 2004b) and the S5-S6 linker of DIV of 
Nav1.4 (Makita et al., 1996).  Our results build on these previous findings by connecting VSD 
regulation to altered inactivation kinetics. 
Even though β1 does not affect the voltage dependence of DIII-VSD activation, comparison of 
DIII-VSD deactivation kinetics in the presence of β1, shows that DIII-VSD recovery to the 
resting position upon repolarization is faster and more complete (t100%-10%=16.5±1.6ms at 0mV), 
in contrast to α alone (t100%-10%=23.9±2.3ms at 0mV, p=0.05) (Fig 2.1h, right panel). In 
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previous studies, fast inactivation was shown to immobilize the gating charge displaced by DIII 
and DIV (Armstrong & Bezanilla, 1977; Cha et al., 1999), in particular DIII-VSD (Sheets & 
Hanck, 2005; Varga et al., 2015). Our result suggests that β1 allows the DIII and DIV VSDs to 
recover to the resting state more quickly. Given the link to inactivation, this more rapid recovery 
of the VSDs will allow channels to recover more quickly from inactivation (Fig 2.1d), and 
become available for excitation in a shorter amount of time.  
β3 alters channel activation and inactivation by modulating DIII- and DIV-VSD kinetics 
We co-expressed the β3 subunit with Nav1.5 using the same protocols that were used for β1 (Fig 
2.2a). As with the β1 subunit, β3 had no apparent effect on voltage dependence of channel 
activation (G-V) (Fig 2.2b), but slowed ionic current activation and inactivation kinetics (Fig 
2.2c). It also caused a depolarizing shift (ΔV1/2=8.7±1.5mV, p=0.02) in SSI (Fig 2.2b), implying 
that β3 expression increases Nav1.5 channel availability at higher potentials. A similar β3-
induced SSI shift was also present in HEK cells, recorded with identical protocols. Unlike β1, β3 
does not significantly alter channel recovery kinetics (Fig 2.2d). When we co-expressed β3 with 
the four VCF constructs, the gating effects of β3 were preserved, except with the DII-LFS 
construct, where the shift in SSI induced by β3 is less pronounced.  Our observations of the ionic 
current changes induced by β3 co-expression are consistent with the gating effects shown 
previously in oocytes (Fahmi et al., 2001) and the scn3b knock-out mouse phenotype (Hakim et 
al. 2008).    
Like β1, β3 caused a depolarizing shift in the Q-V curve at negative potentials and a steeper Q-V 
relationship (Δk=8.6±3.0 mV, p=0.05), showing that β3 also alters the voltage-dependence of 
VSD activation. Considering the homology between the β1 and β3 subunits, the similar Q-V 
curves are not surprising. However, comparison of the F-V curves of α alone and α with β3 
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shows that β3 induces a depolarizing shift in the DIII F-V curve (DIII F-V: ΔV1/2 =20.7± 3.9mV, 
p=0.01), in addition to its depolarizing effect on the DIV F-V (DIV F-V: ΔV1/2 =25.0± 7.7mV, 
p=0.01) (Fig 2.2h, i), causing both the DIII and DIV-VSDs to activate at higher potentials.  The 
DIV F-V depolarizing shift occurs over the same potential range as the shift in SSI, consistent 
with the findings that DIV-VSD activation strongly correlates with channel inactivation, and 
with the above experiments with β1.  
Channel opening is known to be regulated by DIII-VSD activation (Muroi et al., 2010; Wang et 
al., 2016). Yet, β3 induced depolarization of DIII-VSD activation without affecting channel 
voltage-dependence of activation (G-V), which may be due to DIII-VSD activation at very 
negative potentials in the NaV1.5 paralog. Still, β3 slowed ionic current activation kinetics (α 
alone: dI/dtmax=1.6±0.1 ms
-1; α+β3: dI/dtmax=1.1±0.1 ms-1, p=0.04) (Fig 2.2c), suggesting that 
when channels are co-expressed with β3, DIII-VSD activation becomes a rate-limiting factor for 
pore opening. We note that slower inactivation rates can also result in slower activation kinetics 
when normalized currents are compared, since channel activation and inactivation are tightly 
coupled. Thus, the slowed activation kinetics we observed with β3 could alternatively be caused 
by slowed inactivation kinetics.  In contrast to β1, β3 only accelerates DIII-VSD deactivation 
(α+β3: t100%-10% =9.2±1.3ms, α alone: t100%-10% =23.9±2.3ms, p=0.005), but not DIV-VSD 
deactivation (Table 4).  In the NaV1.5 channel, the DIII-VSD activates at very negative 
potentials (~160mV). Thus, it is a technical challenge to acquire the negative baseline of the DIII 
F-V for the more hyperpolarized shifted constructs (α alone and α+β1). Despite this limitation, 
we expect the hyperpolarized shifted constructs would have more negative V1/2 if we were able 
to record to the baseline, suggesting that the DIII depolarizing shift induced by β3 is even larger 
than reported. 
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Figure 3.2 Nav β3 subunit affects Nav1.5 inactivation by modifying both DIII and DIV-VSD activation. 
Nav1.5 ionic currents and site-specific fluorescence changes are measured as described in Figure 1. Groups of 3-10 
cells are reported as mean ± SEM. 
a) Topology of Nav1.5 and NaV β3 subunits on plasma membrane. The NaV β3 subunit structure is homologous to 
the β1 subunit, and it also has been shown to express in the myocardium (Hu et al., 2012). b) Voltage-dependence of 
activation (G-V), and steady-state inactivation (SSI) for WT Nav1.5 with β3 (α+β3, squares), or without β3 (α, 
circles). c) Representative current traces of WT channel with β3 (black), or without β3 (grey) in response to 
depolarizing pulse to 0mV from -120mV. Channels with β3 show slower activation and deactivation kinetics, 
compared to α alone. d) Time dependence of fraction of current recovered for channels with β3 (α+β3, black 
square), or without β3 (α, grey circle). The same protocol was used as described in Fig.1. e) Gating charge-voltage 
curve (Q-V) for WT-LFS Nav1.5 with β3 (α+β3, squares), or without β3 (α, circles). (f-i) Left panel, Voltage-
dependence of Fluorescence (F-V curve) from four VCF constructs f) DI-V215C, g) DII-S805C, h) DIII-M1296C, 
and i) DIV-S1618C co-expressed with (α+β3, square), or without β3 subunit (α, circle). F-V curves are constructed 
and recorded as in Fig. 1. β3 co-expression causes depolarizing shifts in DIII and DIV F-V, without significantly 
affecting the other two domains. Right panel, Representative fluorescence signals representing the kinetics of each 
VSD activation.  
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Despite being highly homologous to β1, β3 is unique in altering the VSD transitions of both DIII 
and DIV.  The DIV-VSD effects induced by β3 are similar to β1, causing a depolarizing steady-
state inactivation shift.  The β3 effect on the DIII-VSD, which shifts DIII-VSD’s activation to 
higher potentials, slows ionic current activation and inactivation kinetics. Two α-β3 interaction 
mechanisms could explain the changes in the VSD movements that we observed. One possibility 
is that β3 can interact with both DIII and DIV. A second plausible mechanism is that β3 mainly 
interacts with the DIII-VSD, which can allosterically modify the adjacent DIV-VSD activation. 
  DI  DI+Β1 DI+Β3 DII DII+Β1 DII+Β3 
G-V V1/2 -42.3±1.7 -50.2±1.0 -37.1±1.8 -33.9±2.2 -38.9±3.0 -43.5±2.2 
 k [n] 8.16±0.7 [5] 8.3±0.6 [4] 9.7±0.5 [4] 9.5±0.2 [4] 8.5±1.2 [9] -7.0±0.5 [4] 
SSI V1/2 -96.3±4.55 -78.6±2.1 -79.6±2.4 -88.8±1.3 -79.2±4.5 -86.4±0.7 
 k [n] -11.0±1.1 [4] -6.4±0.2 [8] -7.0±0.4 [4] -8.2±0.4 [4] -6.5±0.9 [7] -6.1±0.1 [4] 
F-V V1/2 -111.5±1.0 -92.1±11.4 -75.7±4.6 -48.4±2.7 -51.1±3.5 -45.5±5.0 
 k [n] 21.3±2.4 [4] 18.6±2.3 [4] 15.3±2.5 [4] 19.4±0.7 [4] 23.1±2.2 [6] 19.3±0.8 [4] 
  DIII DIII+β1 DIII+β3 DIV DIV+β1 DIV+β3 
G-V V1/2 -43.7±1.9 -40.0±4.4 -39.2±1.4 -36.8±1.6 -34.6±3.4 -38.2±1.3 
 k [n] 7.8±0.6 [5] 9.4±0.7 [13] 7.4±0.5 [6] 8.9±0.9 [4] 9.2±0.6 [19] 7.2±0.5 [5] 
SSI V1/2 -94.7±1.9 -76.2±2.5 -86.0±1.6 -91.7±3.4 -74.2±3.1 -78.0±1.6 
 k [n] -9.8±0.7 [4] -6.7±0.4 [7] -7.6±0.4 [4] -12.6±0.9 [5] -10.3±0.9 [13] -9.2±0.5 [5] 
F-V V1/2 -120.7±4.8 -122.1±1.4 -98.0±2.6 -88.2±5.3 -56.8±6.6 -63.2±4 
 k [n] 25.6±0.7 [4] 24.3±1.3 [5] 26.4±2.0 [5] 23.6±3.1 [4] 14.5±2.5 [6] 14.4±0.3 [4] 
  DIII+β1+β3 DIV+ β1+β3 
G-V V1/2 36.5±0.8  
 k [n] 7.9±0.3 [3]  
SSI V1/2 -80.4±1.1  
 k [n] -6.6±0.1 [3]  
F-V V1/2 -79.8±3.2 -59.2±0.8 
 k [n] 29.7±1.8 [5] 13.2±1.1 [3] 
Table 2.1  Parameters of Boltzmann fit to G-V, 
SSI and F-V curves for WT Nav1.5 or VCF 
constructs expressed with or without WT β1 or 
β3. 
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Below, results from β1/β3 chimera and α-β3 quencher fluorophore pair experiments support the 
latter mechanism.  
High expression of β3 separates DIII-VSD activation into two steps 
To ensure that the VSD alterations we observed were truly caused by expression of β subunits, 
and the amount of β subunits expressed on membrane saturated their modulation effects of 
NaV1.5 channels, we tested different expression levels of β subunits. We altered β subunit 
expression levels by injecting mRNAs encoding α and β subunits at different molar ratios, 
observing their effects on ionic current and VSD activation.  
For the β1 subunit, as we increased the mRNA molar ratio from 1:1 to 1:2, the DIV F-V shifted 
to more depolarized potentials (1:1 α:β1: V1/2 =-70.1± 5.2mV, 1:2 α:β1: V1/2 =-56.8± 5.0mV). 
Further, when the α:β1 mRNA molar ratio was increased to 1:4, the DIV F-V curve overlaps 
with F-V of a 1:2 α:β1 mRNA molar ratio (Fig 2.3a), suggesting that β1 modulation of DIV-
VSD saturated at 1:2 α:β1 ratio. Consistently, the β1 alteration of channel SSI followed a similar 
saturation pattern (Fig 2.3b). This result further supports the idea that β1 regulates channel 
inactivation by altering DIV-VSD activation, an effect that saturates at a 1:2 ratio. 
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Figure 2.4 High expression of β3 subunits separate DIII-VSD movements into two components. a-b) DIV VCF 
construct (α) was co-injected with β1 mRNA at molar ratios of 1:1, 1:2, 1:4, or without β. c-d) DIII VCF construct 
(α) was co-injected with β3 mRNA at molar ratios of 1:1, 1:2, 1:4, 1:6, or without β. e) Comparison between 
channel recovery from inactivation curves for α: β3 at 1:2 and 1:6. f) Representative channel recovery from 
inactivation current traces at 1:6 α: β3 molar ratio. Dotted line represents the first pulse peak amplitude. g) DIII 
fluorescence trace at 1:6 α: β3 molar ratio, in response to 0mV depolarizing potential. In parallel to DIII 
fluorescence voltage dependence, the DIII fluorescence activation kinetics also display two components F1 and F2. 
h) Schematic model of DIII-VSD movements when channels are co-assembled with high expression level of β3. i) 
Comparison of the current activation kinetics show that with high expression of the β3 subunit, the second current 
pulse after short recovery time has faster activation kinetics.  
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For β3, the saturation behavior was more complex. When we increased the mRNA molar ratio 
from 1:1 to 1:2, the DIII F-V curve shifted to depolarized potentials (1:1 α:β3: V1/2 =-108.6± 
5.6mV, 1:2 α:β3: V1/2 =--97.9± 2.6mV) (Fig 2.3c). Intriguingly, when the molar ratio of α:β3 is 
increased to 1:4 or higher, the DIII F-V curve started to exhibit two components, which could no 
longer be fit with a single Boltzmann function (Fig 2.3c). The curve was well-fit with two 
Boltzmann curves, one at very negative potentials (-180mV to -80mV), and the other within the 
channel activation voltage range (-80mV to 20mV). Correspondingly, the DIII fluorescence 
kinetics also followed two steps, which were also not well-fit with a single exponential. The first 
rapid transition occurred within 2ms after depolarization, denoted by F1, followed by a very slow 
component, denoted by F2 over 60ms time course (Fig 2.3g).  
The separation of two components in DIII-VSD activation caused unusual recovery from 
inactivation, where the peak current magnitude during the test pulse was larger than the control 
pulse following recovery times of 10 to 300 ms (Fig 2.3e, f). After 500-1000ms recovery at -
120mV, the peak current during the test pulse returned to the magnitude of the control pulse. 
Typically, Na+ currents exhibit monotonic behavior during this protocol. 
We assessed the relationship between the two DIII-VSD activation components and channel 
recovery from inactivation by aligning current during the first control pulse with that of the 
second test pulse after 10 ms or 1000 ms recovery (Fig 2.3i bottom left, top right). For channels 
expressed without the β subunit, current during the test pulse after 10ms recovery activated at the 
same rate as the control pulse (Fig 2.3i top left). For channels co-expressed with β3 subunit at 
1:4 molar ratio, current during the test pulse after 10 ms recovery activated more quickly in 
comparison to the control pulse (Fig 2.3i bottom left). In contrast, the current during the test 
pulse after 1000 ms recovery rose at the same rate as that of the control pulse (Fig 2.3i top 
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right). Faster channel activation kinetics can significantly increase peak current. High β3 
expression causes faster activation kinetics during a test pulse that follows a short recovery 
interval (10-300ms), resulting in peak current that exceeds the control pulse current.   
To account for this behavior, we first suppose that the DIII-VSD activates in two steps from 
resting (R) to intermediate activated (A1), and activated states (A2) (Fig 2.3h). We then assume 
that the transition between R to A1 is fast, and is described by F1 component, while A1 to A2 is 
slow, as shown by F2 component. In this model, pore opening is facilitated by the transition of 
the DIII-VSD to the A1 state and further encouraged by entry into the A2 state. During the first 
200 ms pulse, most DIII-VSDs are brought to A2. Since the transition from A2 to A1 state is 
slow, when channels were given 10-300ms to recover at -120mV, the time was too short for 
DIII-VSD to recover to A1, resulting most of the DIII-VSDs being trapped in the A2 state. As 
most of DIII-VSDs were still in A2 state and it greatly facilitates pore opening, channel 
activation was faster for the second pulse. If this scheme is correct, we would predict that if we 
only allow the DIII-VSD to enter A1 by applying a short 2ms depolarizing pulse as the control 
pulse, the second pulse will not have faster rising kinetics compared to the control pulse. Indeed, 
comparison of the control and test pulses show that both pulses completely overlap (Fig 2.3i 
bottom right).  
It is unlikely that the physiological assembly of α-β3 will reach such high ratio to separate DIII-
VSD movement into two components (Yuan et al., 2014). It is possible that overexpression of β3 
forces some of the β3 subunits in a secondary low-affinity binding site. Consequently, if β3 is 
locally expressed at very high levels, this group of cells will have a relatively short refractory 
period and become particularly excitable, because of the unique channel recovery behavior.   
β1 and β3 do not regulate VSD activation from the NaV1.5 pore via the S4-S5 linkers 
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By probing the VSD dynamics, we discovered that β1 and β3 modulate channel current by 
altering DIII and DIV VSD activation. However, the mechanism by which the β1 and β3 
subunits interact with the NaV channel to alter VSD activation remains unclear. The recent Cryo-
EM structure of eukaryotic NaV channel shows that the pore loops of NaV channel have bulky 
extracellular structures, making them good candidates for β subunit binding (Shen et al., 2017). 
To test if β1 and β3 subunits allosterically modulate the VSDs by interacting with the DIII and 
DIV pore domains, we assessed β1 and β3’s effects on mutant channels where DIII or DIV-VSD 
is decoupled from the pore. The interaction between the S4-S5 linker and the S6 is known to be 
essential for canonical coupling between the VSD to the pore of each domain. We utilized 
mutations that were previously found to disrupt this type of coupling.  
 
Figure 2.4 β1 and β3 modulate the DIII and 
DIV VSDs, even when the VSDs are 
decoupled from the pore.  
a) β1 co-expressed with the N1765A mutant 
channel. b) β3 co-expressed with the A1330W 
mutant channel. c) β1 co-expressed with the 
N1765A mutant channel.  
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Residue N1765, which is on the S6 of DIV, was previously shown to be essential for coupling 
the DIV-VSD to the pore (Sheets et al., 2015). Mutating N1765 to Alanine (A) abolishes most of 
the ionic current (Fig 2.4a) without affecting DIV-VSD movement and gating currents, 
suggesting that the DIV-VSD is decoupled from the pore. Co-expressing β1 with the N1765A 
channel still depolarized the Q-V curve and the DIV F-V (Fig 2.4a), similar to the β1 effect on 
WT channels. If β1 interacts with the DIV-pore domain to allosterically modulate the DIV-VSD 
through the S4-S5 linker, decoupling of the DIV-VSD from the DIV-pore domain should abolish 
most of the β1 effect on the DIV-VSD. Instead, we found that the DIV-VSD of the N1765A is 
still modulated by β1, suggesting that β1 does not regulate the DIV-VSD via pore coupling 
through the DIV S4-S5 linker, but instead interacts with the DIV-VSD directly or via an 
alternative pore-VSD coupling mechanism. 
Since β3 was shown to alter DIV-VSD activation (Fig 2.2), we also tested the β3 effect on the 
N1765A channel. Like β1, β3 still causes depolarizing shifts in the DIV F-V curve (Fig 2.4c) and 
voltage dependence of gating charges (Q-V) of the N1765A channel, suggesting that β3 does not 
interact with the DIV pore domain to regulate DIV-VSD activation via the S4-S5 linker. In 
addition to the DIV effect, we also showed that DIII-VSD is significantly affected by β3. We 
assessed the β3 effects on channels that contain a mutation that decouples the DIII-pore from its 
VSD. A1149, located on the DIII S4-S5 linker of NaV1.4, is one of the key residues on the gating 
interface (Muroi et al., 2010). Mutating A1149 to W in the NaV1.4 stabilizes the activated DIII-
VSD, but not the pore, suggesting that the coupling between the DIII-VSD to the DIII-pore is 
reduced (Muroi et al., 2010). The homologous residue in the NaV1.5 isoform is A1330. 
Consistent with previous studies, A1330W greatly hyperpolarized the DIII F-V curve, compared 
to WT. However, ionic current activation (G-V) was not significantly affected. When co-
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expressed with β3, the DIII F-V was still significantly depolarized (ΔV1/2=22.6±6.7, p=0.03), 
compared to A1130W alone (Fig 2.4b). This result suggests that β3 does not regulate DIII-VSD 
activation via S4-S5 linker coupling to the DIII-pore domain.  However, there are alternate 
means to compule the pore to the VSD, including the DIII-DIV linker, and these alternative 
mechanisms could possibly be in play.   
 Assessing β subunit localization 
Since we observed that β1 and β3 modulate channel gating by affecting the DIII and DIV VSDs, 
we hypothesized that β1 and β3 are proximally located to these VSDs. To test this hypothesis, 
we introduced a fluorophore or a quenching tryptophan into the β subunit. This method was 
previously applied to other proteins, such as T4 lysozyme (Mansoor et al., 2010; Mansoor, 
Mchaourab, & Farrens, 2002) and the BK channel (A. Pantazis & Olcese, 2012) to map distances 
within proteins. We reasoned that if β1 or β3 resides near one of the channel’s VSDs, 
introducing a tryptophan residue to the top of the transmembrane segment of β1 or β3 would 
quench the fluorophore attached to the S3-S4 linker of that VSD.   
We first introduced a tryptophan mutation to the extracellular region of the β1 transmembrane 
segment, S156W. Compared to WT β1, S156W β1 only slightly depolarizes the DI and DIV F-V 
curves, but none of the domains’ fluorescence signal was significantly quenched. This result 
suggests that the β1 transmembrane segment is not within detectable quenching distance to the 
S4s of any domain.  
We then introduced a tryptophan mutation into the extracellular region of the β3 transmembrane 
segment, S155W. S155W β3 did not affect DI, DII or DIV F-V curves or fluorescence compared 
to WT β3, but the fluorescence of the DIII-VSD was completely reversed (Fig 2.5a). In the DIII- 
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LFS construct, the DIII-VSD fluorescence signal moves downward upon membrane 
depolarization (Fig 2.2h).  This reduction in fluorescence is consistent with local environment 
quenching of the fluorophore attached to the S3-S4 linker of DIII upon activation. In contrast, 
when S155W β3 is present, its tryptophan strongly quenches the fluorophore on the DIII S3-S4 
linker when S4 is at resting position. When S4 activates, the fluorophore moves away from the 
tryptophan, resulting in an increase in fluorescence. This result shows that the β3 subunit resides 
very near to the DIII-VSD at a distance that is within the van der Waals contact distance (5-15 
Å) (Mansoor et al., 2002). Notably, the DIII fluorescence kinetics with S155W β3 are greatly 
slowed, and the F-V curve has similar voltage dependence (V1/2=-67.2±3.5mV) as the second 
component of DIII F-V with high β3 expression (Fig 2.3c). Thus, the DIII fluorescence with 
S155W β3 tracks a slower component of the DIII-VSD that occurs at higher potentials, a 
component which is observed but not prominent with the LFS construct.  
 
Figure 2.5 tryptophan-induced quenching of the fluorophore method reveals β3 proximity to the DIII-VSD  
a) Side view and top view showing the proposed location of the β3 subunit with respect to the channel. A tryptophan 
mutation is made on of the extracellular β3 domain. Fluorescence-voltage (F-V) curve of DIII-LFS co-expressed 
with S155W β3(triangles), in comparison to F-V curve of DIII-LFS co-expressed with WT β3 (dotted line). b) Side 
and top view showing WT α subunit co-expressed with S155C β3 that is labeled with MTS-TAMRA. F-V curve of 
WT α co-expressed with the labeled S155C β3 (diamond), compared to the DIII-LFS co-expressed with WT β3 
(dotted line).   
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If β3 and the DIII-VSD are close in proximity, we would also expect to track DIII-VSD 
conformational changes by labeling the β3 subunit. To test this hypothesis, we introduced a 
cysteine into the extracellular β3 segment, S155C. We co-expressed S155C β3 with the WT 
NaV1.5 α subunit in Xenopus oocytes. We then labeled the S155C β3 with a fluorophore (MTS-
TAMRA). A voltage-dependent fluorescence signal was detected (Fig 2.5b). Changes the local 
environment of the fluorophore attached to β3 when DIII-VSD changed conformation likely 
produced this signal. The F-V curve of WT α subunit with labeled S155C β3 is comparable to 
the F-V curve of labeled DIII-LFS α subunit with WT β3 subunit (Fig 2.5b). This result suggests 
that the fluorescence signal generated by the labeled β3 represents the conformational changes of 
DIII-VSD.   
Using the tryptophan-induced fluorophore quenching method (Mansoor et al., 2010, 2002; A. 
Pantazis & Olcese, 2012), we demonstrated β3’s proximity to the DIII-VSD. Given that β3 still 
affects the DIII-VSD that is decoupled from the pore by the A1330W mutation, and the location 
of the β3, we conclude that β3 modulates DIII-VSD by direct interaction. Taking advantage of 
β3 proximity to the DIII-VSD, we are now able to track the DIII-VSD conformation without 
directing labeling the α subunit.  
β1 and β3 chimeras show that both the extracellular and transmembrane domains of β3 are 
essential for its interaction with the DIII-VSD 
We observed that β1 and β3 have distinct interactions with channel VSDs, especially the DIII-
VSD. In response, we sought to further understand which part of the β subunit is essential for 
these interactions. We created 3 chimera β1 and β3 subunits (Fig 2.6a), one with the β3 
extracellular domain and β1 transmembrane and intracellular domain (β3-N β1-TMC), one with  
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Figure 2.6 β1/β3 chimeras reveal that both extracellular and transmembrane domains of β3 are essential for 
its modulation of DIII-VSD a) Three β1/β3 chimeras were created, β3-N β1-TMC, β1-N β3-TMC, β3-NTM β1-C, 
based on predicted extracellular, transmembrane, and intracellular sequences from Uniprot. mRNA encoding β1/β3 
chimeras and DIII or DIV VCF constructs were co-injected at a molar ratio of 3:1. b-d) DIII F-V curve with β1 
(yellow line), β3 (blue line), β1/β3 chimera (black diamond), or without β (grey line). e-g) DIV F-V curve with β1 
(yellow line), β3 (blue line), β1/β3 chimera (black diamond), or without β (grey line).  
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the β1 extracellular domain and β3 transmembrane and intracellular domain (β1-N β3-TMC), 
and one with both extracellular and transmembrane domains of β3 and the β1 intracellular 
domain (β3-NTM β1-C). Comparison of the DIII F-V curves for all three chimeras illustrates 
that both the extracellular and transmembrane domains of β3 are necessary for its modulation of 
the DIII-VSD activation, since only the chimera that contains both extracellular and 
transmembrane domains of β3 (β3-NTM β1-C) caused a depolarizing shift in DIII F-V (Fig 
2.6d) compared to α alone (ΔV1/2 =22.9±5.0mV, p=0.003), resembling the shift induced by WT 
β3 subunit (ΔV1/2 =20.7± 3.9mV, p=0.01). The other two β1/β3 chimeras caused no shift in DIII 
F-V curve compared to α alone, resembling the β1 subunit effects (Fig 2.6b, c).  
The DIV-VSD response to these β1/ β3 chimeras is more difficult to interpret, because both WT 
β1 and β3 cause comparable depolarizing shifts in the DIV F-V (Fig 2.1, 2.2). Notably, the β3-N 
β1-TMC chimera causes a larger depolarizing shift of the DIV-VSD (ΔV1/2 =32.7± 1.2mV, 
p=0.001) than β1 or β3 (Fig 2.6e). Both β1-N β3-TMC and β3-NTM β1-C cause DIV F-V 
depolarization that is similar to WT β1 or β3 (Fig 2.6f, g). This result suggests that the 
interaction of the β3 extracellular domain with the channel can cause additional modulation of 
the DIV-VSD, and induce an interaction mechanism that is distinct from the transmembrane and 
C-terminus of the β1 subunit.  Previously, we observed that the WT β1 subunit causes the DIV-
VSD to deactivate more quickly (fig 2.1). Comparing DIV-VSD deactivation kinetics of these 
chimeras, we note that both β3-N β1-TMC and β3-NTM β1-C chimeras that contain β1 C-
terminus, resemble the fast DIV deactivation induced by WT β1 (β3-N β1-TMC: t100%-
10%=3.9±0.6ms, p=0.0002 compared to α alone; β3-NTM β1-C: t100%-10%=3.7±0.3ms, p=0.0004, 
compared to α alone), suggesting that the β1 C-terminus is important for speeding DIV-VSD 
deactivation upon membrane repolarization.   
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By monitoring DIII- and DIV-VSD conformations in the presence of β1/ β3 chimeras, we found 
that the extracellular and transmembrane domains of β3 subunit are essential for depolarizing 
DIII-VSD activation, which controls channel current activation kinetics. The C-terminus of β1 is 
essential for speeding DIV-VSD deactivation kinetics upon membrane repolarization, which will 
affect channel recovery from inactivation.  
β1 and β3 effects on the DIII- and DIV-VSDs are not independent  
Both β1 and β3 have been shown to express in the ventricular myocardium (Fahmi et al., 2001; 
M S Olesen et al., 2011), to modify Nav1.5 gating in concert. To assess the molecular 
consequences when both β1 and β3 subunits are expressed, we co-injected mRNA of the α, β1, 
and β3 subunits at a molar ratio of 1:3:3 (Fig 2.7a). As with co-expression of β1 or β3, 
simultaneously co-expressing the channel with both causes a depolarizing shift in the SSI curve 
(Fig 2.7b), compared to the α subunit alone. The magnitude of this shift is not significantly 
different to the shifts induced by β1 or β3 (Fig 2.7b), raising two possible mechanisms. One 
explanation is that only one of the β1 and β3 subunits can co-assemble with the α subunit at a 
time, so that the shift is an average of the shifts induced by either β1 or β3. The other possibility 
is that β1 and β3 binding to the α subunit is not exclusive, and there might be some cooperation 
and interaction between the β1 and β3 that are bound to the same α subunit. The latter 
mechanism appears more likely, as we also observe a depolarizing shift in the G-V curve caused 
by co-expression with both β1 and β3 subunits (ΔV1/2 =7.2± 2.3 mV, p=0.02) (Fig 2.7b), which 
was not seen in α with only β1 or β3.   
To gain insight into potential interaction mechanisms between β1 and β3, we assessed the co-
expression of both β1 and β3 on the activation of each VSD. Co-expression of β1 and β3 have 
minimal effects on DI- and DII-VSD activation, as no significant shift was observed in DI and 
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DII F-V (Fig 2.7c, d), consistent with previous observation that β1 and β3 do not perturb DI- or 
DII-VSDs. Compared to α alone, co-expression with both β1 and β3 caused a depolarizing shift 
in the DIII-VSD (Fig 2.7e). The magnitude of this shift was greater than the linear addition of 
the shifts induced by β1 only, and β3 only (dotted line), suggesting that when both β1 and β3 
were present, they produced additional depolarization of DIII-VSD activation, corresponding to 
the depolarizing shift in channel activation. Thus, we infer that there must be cooperation 
between β1 and β3 that causes a greater effect on the DIII-VSD when both are interacting with 
the channel.    
 
Figure 2.7 Simultaneous co-expression of the β1 and β3 reveals cooperativity between these two subunits.   
a) Both β1 and β3 subunits are co-expressed with Nav1.5 by co-injecting mRNAs encoding Nav1.5, β1, and β3 at a 
molar ratio of 1:3:3. b) Voltage-dependence of activation (G-V), and steady-state inactivation (SSI) for LFS-DIII 
Nav1.5 co-expressed with β1 (square), β3 (square), β1+ β3 (triangles), or without β (circle). c-f) DI-DIV F-V curve 
with β1 (square), β3 (square), β1+ β3 (triangles), or without β (circle) co-expressed. The dotted line represents the 
sum of the shifts induced by β1 and β3, with respect to no β. 
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In contrast, expressing β1 and β3 together caused a DIV F-V depolarizing shift that most closely 
resembles the shift produced by β1 or β3 only (Fig 2.7f), and also corresponds to the SSI shift 
(Fig 2.7b). If β1 and β3 act independently, the DIV F-V shift should resemble the linear addition 
of β1 and β3-induced shifts (Fig 2.7f dotted line). Thus, this result suggests that β1 and β3’s 
modulation of DIV-VSD is not additive.  
Together, these results show that β1 and β3 binding to the NaV1.5 channel is not exclusive, and 
when both β subunits are present, their cooperativity further depolarizes DIII-VSD activation, 
which leads to additional modifications of channel activation. The physiological impact of this 
result is limited, because this experiment was conducted in the condition of overexpressing β 
subunits, which may cause additional binding that may not happen in native cells. More 
information regarding the stoichiometry of α, β1, and β3 in native cells is required to infer the 
physiological consequences of β1 and β3 subunit cooperativity.  
2.4 Discussion  
The non-covalently bound Nav channel β1 and β3 subunits were first identified in 1985 (Messner 
& Catterall, 1985) and 2000 (Morgan et al., 2000a). Despite recent findings showing that these 
subunits play a critical role in regulating neuronal and cardiac electrophysiology (Calhoun & 
Isom, 2014), the precise mechanisms that they use to modulate channel gating have not been 
described.  In this study, we utilized VCF to test the hypothesis that the β1 and β3 subunits 
regulate NaV channel kinetics via the VSDs.  We discovered that WT β1 subunit co-expression 
shifts DIV-VSD activation to depolarized potentials, consistent with the shift in SSI.  β1 subunits 
also relieve the immobilization of the DIII- and DIV-VSDs by fast inactivation, which 
potentially contributes to the increased rate of channel recovery from inactivation induced by β1.  
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The WT β3 subunit also regulates channel inactivation with a corresponding shift in DIV-VSD 
activation.  However, in contrast to β1, there is a prominent WT β3 interaction with the DIII-
VSD. We believe β3 modulation of DIII-VSD is primary, since we showed that the 
transmembrane domain of β3 is very close to the DIII S4 by tryptophan-induced fluorophore 
quenching. Moreover, β1/β3 chimeras mainly affect the DIII-VSD without changing DIV-VSD 
activation.  Recently, we showed that DIII-VSD deactivation strongly correlates with channel 
recovery from inactivation, a phenomenon that is determined by the DIII S4-S5 linker’s 
interaction with the inactivation gate after ~100ms pulses (Hsu et al., 2017b). Here, we observed 
that β3 does not affect channel recovery from inactivation, even though it speeds DIII-VSD 
deactivation, suggesting that β3 possibly disrupts the interaction between the DIII S4-S5 linker 
and the inactivation gate, abolishing DIII-VSD regulation of recovery from inactivation.  
Despite the β1 and β3 subunits being homologous, we demonstrate that they have distinct 
interactions with the NaV channel VSDs, resulting different current kinetics and rates of 
inactivation recovery. Consistently, our results from the tryptophan induced quenching 
experiment showed that β1 and β3 assemble with the channel at different locations. As β1 and β3 
have very different spatial and temporal expression patterns in heart (Domínguez et al., 2005; 
Okata et al., 2016), the molecular interactions that we have observed will significantly affect 
their regulation of tissue excitability. For regions that have higher β1 expression, for example 
Purkinje fibers in heart (Domínguez et al., 2005), we would expect cells to be more excitable 
because β1 causes NaV channels recover more quickly and increase channel availability, 
consistent with the Purkinje fiber role of fast conduction of cardiac excitation. During heart 
development, β1 expression increases, while β3 decreases (Domínguez et al., 2005; Okata et al., 
2016). This dynamic temporal expression pattern suggests that β1 contributes more to mature 
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NaV channel properties, such as increased excitability. Thus, we expect that molecular-level 
differences in β1 and β3 regulation of the DIII- and DIV-VSDs will affect organ level behavior. 
β1 and β3 localization within the Nav1.5 channel complex 
The β1 subunit has been found to express and co-assemble with both neuronal and cardiac Nav 
channels (Isom et al. 1992b). There is a general consensus that when β1 co-assembles with 
NaV1.5, it regulates steady-state inactivation (Calhoun & Isom, 2014). However, the direction 
and magnitude of the inactivation shift varies depending on the expression system used and 
protocols applied (Calhoun & Isom, 2014). This variability may be linked to the interaction 
between β1 and other members of the macromolecular NaV channel complex in native cells, such 
as Ankyrin G (Malhotra et al. 2002). Thus, the nature of β1-α interaction may vary by expression 
system, precluding the identification of a universal phenotype.  
Several α-β1 interaction sites have been proposed. On the α subunit, a C-terminal mutation was 
able to eliminate β1 regulation of NaV1.1 current kinetics (Spampanato et al., 2004a), and 
NaV1.4/NaV1.5 chimeras show that the S5-S6 linker of DIV plays a role in α-β1 interaction 
(Makita et al., 1996).  Both results suggest that binding occurs near the DIV domain.  Aside from 
the consequences of direct binding, the β1 subunit has also been shown to introduce the surface 
charges that electrostatically affect channel gating (Ferrera & Moran, 2006). We observed that 
WT β1 mainly affects the voltage dependence of DIV-VSD activation and its deactivation 
kinetics through possible direct interaction with the DIV-VSD, which suggests β1 proximity to 
the DIV-VSD. Together, these results support the hypothesis that β1 modulates inactivation by 
altering DIV-VSD activation. We infer that β1 most likely resides in the cleft between the DIII 
and DIV-VSD (Fig 2.8a, b). 
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Figure 2.8 Proposed model for β1 and β3 assembly with NaV1.5 channel a) Extracellular view of the Nav1.5 
channel based on the Navab structure (Payandeh, Scheuer, Zheng, & Catterall, 2011). b) Side view of NaV1.5, co-
assembled with β1 subunit. Only DIII (blue), and DIV (pink) are shown for clarity. Our model suggests β1 locates in 
the cleft between the DIII-VSD and DIV-VSD, allowing it to interact with the DIV VSD, C-terminus, and 
potentially S4-S5 linker of DIV, to modify DIV-VSD movements. c) Side view of Nav1.5 (rotated 90ᴼ), co-
assembled with β3 subunit. Our model suggests β3 locates in the cleft between the DIII-VSD and DII-VSD, next to 
S4 of DIII, allowing it to strongly modify DIII-VSD activation, and affecting DIII-VSD to pore coupling by 
interacting with the hinge connecting S4 and S4-S5 linker of DIII.   
The β3 subunit is homologous to β1, and also interacts with Nav channels non-covalently. Less is 
known about the α-β3 interaction. Because the β1 and β3 subunits are homologous (50%), it has 
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been generally supposed that β3 interacts with the channel via the same mechanism as β1 
(Namadurai et al., 2015). In contrast, we found that the WT β3 subunit caused a large 
depolarizing shift in DIII-VSD activation, in addition to the DIV shift. The depolarization of 
DIII-VSD activation slowed down ionic current activation and inactivation kinetics, allowing the 
DIII-VSD to play a more prominent role in regulating this gating over a physiological range of 
potentials. Further, we demonstrated β3 proximity to the DIII S4 segment, as we observed that a 
tryptophan mutation on the top of β3 subunit strongly quench the fluorophore attached to the 
DIII S3-S4 linker. It is most likely that β3 is adjacent to the DIII S4 segment, in the cleft between 
the DII and DIII VSDs, which allows β3 to directly interact with the DIII-VSD. Altered DIII-
VSD activation can then allosterically affect DIV-VSD activation. Yet, we observed that β3 still 
depolarized the DIV-VSD when the DIV-VSD to pore coupling via the S4-S5 linker was 
abolished by the N1759A mutation, suggesting that this coupling to the DIV-VSD takes place 
via alternative mechanisms, such as the DIII-DIV linker.  
The importance of β3 in maintaining normal cardiac function has been highlighted by scn3b 
knock-out mice. These mice exhibit slowed sino-atrial and atrioventricular conduction, burst-
pacing-induced atrial tachycardia, fibrillation, and ventricular tachycardia (Hakim et al. 2010; 
Hakim et al. 2008). Consistent with our results (Fig. 2.2), knocking out β3 shifts Nav SSI to 
negative potentials, reducing peak Na+ current in the ventricle, which causes slowed conduction 
and decreased action potential duration in the endocardium and epicardium. Given the 
consistency of the knockout mouse phenotype with our results, we infer that β3 regulation of the 
NaV1.5 DIII and DIV-VSDs significantly determines action potential morphology and 
conduction.  
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When we expressed β1 and β3 together, we observed enhancement of the depolarizing DIII-VSD 
shift and an exclusive effect of β1 on the DIV-VSD (Fig. 2.6). These results imply that the 
subunits do not interact with the channel independently. Consistently, previous work has shown 
that heterophilic interaction between the β1 and β3 subunits can occur via their respective Ig 
domains (Yereddi et al., 2013), which could possibly alter their interaction with each VSD.  β3 
binding to β1 may affect its interaction with the DIII-VSD.  Our proposed localization of β1 and 
β3 would bring the extracellular domains of both subunits near to the DIII-S4 (Fig 2.8).  In sum, 
our results show that both the β1 and β3 subunits are likely able to co-assemble with a single 
Nav1.5 channel complex and that this co-assembly significantly affects channel function. 
Each domain of β1 and β3 has distinct interactions with NaV1.5 channel 
By measuring VSD conformation in the presence of β1/β3 chimeras, we showed that both the 
extracellular and transmembrane domains of β3 are necessary for β3 depolarization of the DIII-
VSD. When channels were co-expressed with β1/ β3 chimeras containing the β3 extracellular 
domain and the β1 transmembrane and intracellular domain, DIII-VSD activation was not 
depolarized, suggesting that the transmembrane domain of β3 is critical for localizing the β3 
subunit to this location in NaV1.5, allowing the extracellular Ig domain of β3 to interact with the 
DIII-VSD. We also showed that the C-terminus of the β1 subunit is necessary for relieving DIV-
VSD immobilization, and the β3 C-terminus is important for relieving DIII-VSD immobilization 
from fast inactivation. Previously, we showed that the interaction between the fast inactivation 
gate (IFM) and the N1659 residue on DIV S4-S5 linker plays important role in immobilizing 
DIII and DIV-VSD. It is plausible that the β1 C-terminus can interact with the intracellular DIV-
S5 segment, altering this interaction.  These results show that β1 and β3 could interact with the 
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NaV channel through multiple interaction sites, and that both the extracellular domain and C-
terminus play important roles in determining their gating properties. 
Two step movements of DIII-VSD revealed by high expression of β3.  
Like KV channels, two step transitions of NaV channel VSDs have been proposed, based on 
previous observations that pulses of increasing duration alter the DIII-VSD deactivation rate 
(Hsu et al., 2017b; Varga et al., 2015). Our results support this suggestion by showing that high 
levels of β3 subunit expression cause two prominent components of DIII-VSD activation. This 
phenomenon is similar to KCNQ1 channels that show two step activation in the presence of 
KCNE1 that stabilizes the activated-VSD closed-pore state and slows ionic current activation 
(Barro-Soria et al., 2014). Similarly, the activation of Na+ current is slower when β3 separates 
the DIII-VSD transition into two components. Additionally, since NaV channels have very fast 
and prominent inactivation, the separation of DIII-VSD movement will increase the amplitude 
Na+ current as the channels are excited repetitively at relatively high frequency (>3Hz). 
Our study shows that β1 and β3’s differential interactions with the DIII and DIV VSDs 
determine their regulation of Na+ current and cell excitability. These distinct regulatory 
mechanisms are essential for understanding how β subunits regulate excitable cells and how 
mutant β subunits cause disease.  
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2.5 Materials and Methods  
Molecular Biology  
cDNA encoding the human Nav β3 (UniProtKB/Swiss‐Prot accession no. Q9NY72) subunit was 
custom-synthesized by Life Technologies and inserted into the pBSTA plasmid. cRNAs for the 
human β1 subunit (UniProtKB/Swiss‐Prot accession no. Q07699.1) and α‐subunit NaV1.5 
(accession no. Q14524.1) were produced from the pBSTA and pMAX vectors respectively. All 
mutagenesis was accomplished using the QuikChange II site-directed mutagenesis kit (Agilent), 
with primers from Sigma-Aldrich. Multiple colonies were picked and plasmids were isolated 
using the NucleoSpin plasmid miniprep kit (Macherey-Nagel). After samples were confirmed 
with sequencing (Genewiz), a single clone was selected for a Midiprep preparation (NucleoBond 
Xtra Midi, Macherey-Nagel). Each plasmid was then linearized with the NotI or EcoRI 
restriction enzyme, and purified with the NucleoSpin Gel and PCR Clean-up kit (Macherey-
Nagel). Finally, capped mRNA was synthesized in vitro using mMessage mMachine T7 
Transcription Kit (Life Technologies), purified via phenol-chloroform extraction and 
reconstituted to a concentration of ~1 μg/μL.  
Cut-open oocyte recording  
mRNAs for the human α-subunit Nav1.5 and β1 or β3 subunits were injected at a 3:1 molar ratio 
(50-56 ng per cell total) into Xenopus oocytes. Oocytes were then incubated at 18°C in ND93 
solution (mM: 93 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 5 HEPES, and 2.5 Na‐pyruvate, and 1% 
penicillin‐streptomycin, pH 7.4). 3-7 days after injection, cut-open recordings(Rudokas et al. 
2014; Stefani and Bezanilla 1998) were performed using a cut-open amplifier (CA-1B, Dagan 
Corporation) coupled to an A/D converter (Digidata 1440; Molecular Devices). Clampex 
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software (v10, Molecular Devices) was used for data acquisition. During records the temperature 
was maintained at 19°C with a controller (HCC‐100A, Dagan Corporation). The internal 
recording solution was composed of (mM): 105 NMG-Mes, 10 NaMes, 20 HEPES, and 2 
EGTA, pH 7.4, and the external solution was (mM): 25 NMG-Mes, 90 Na-Mes, 20 HEPES, and 
2 Ca-Mes2, pH 7.4.  
Prior to recording, the membrane capacitance compensation and P/–8 leak subtraction were 
applied. The ionic currents were recorded using the standard I-V protocol. From a -120mV 
holding potential, cells were stepped to a 100ms pre-pulse of -120mV, then stepped to test 
potentials ranging from -120mV to 60mV with 10mV increment, preceding by a 100ms post-
pulse of -120mV. For steady-state inactivation, cells were held at test potential for 200ms, then 
tested availability by a depolarizing pulse of -20mV. Gating currents were recorded during test 
pulses from -150 to 50mV from a holding potential of -120mV. Capacitance and leak were 
compensated by P/4 leak subtraction with a subsweep potential of 40mV. Gating charge-voltage 
(QV) curves were constructed by integrating gating currents over 7ms after voltage step. 
Voltage clamp fluorometry 
Before recording, oocytes were labeled with 10 μmol/L methanethiosulfonate-
carboxytetramethylrhodamine (MTS-TAMRA, Santa Cruz Biotechnology) in a depolarizing 
solution (mM: 110 KCl, 1.5 MgCl2, 0.8 CaCl2, 0.2 EDTA and 10 HEPES, pH 7.1) for 30 
minutes on ice. Fluorescence data was collected simultaneously with ionic current on a custom 
rig (Varga et al., 2015), combining cut-open voltage clamp and an epifluorescence upright 
microscope (FN1, Nikon), using a 40X water-immersion objective with 0.8 NA (CFI Plan Fluor, 
Nikon). A green, high-powered LED (Luminus, PT-121) was used for illumination, controlled by 
a driver (Lumina Power, LDPC-30-6-24VDC) by Clampex software. The emission light was 
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measured with a photodiode (PIN-040A, United Detector Technology) mounted on the 
microscope epifluorescence port. The photocurrents generated by photodiode were then 
amplified by a patch clamp amplifier (Axopatch-200A, Molecular Devices). Each fluorescence 
trace is an average of 7-10 fluorescence recordings of the same cell.  
Data analyses  
Data analyses were performed using Clampfit (v10, Molecular Devices), Matlab (R2012a, 
Matlab), and Excel (Microsoft). For fluorescence data, signals were low-pass filtered at 1kHz 
offline, before analysis. To correct for photo-bleaching, the baseline fluorescence trace, which 
has no change in voltage, was fit and subtracted from the traces recorded when the voltage 
protocol was applied.   
Steady state voltage dependence curves (G-V, F-V, SSI) were quantified by fitting a Boltzmann 
function: y= 1/(1+exp[(V-V1/2)/k]). Sample sizes were chosen so that the standard error of mean 
was less than 0.1 for each data point, and a minimum sample size of 3 was determined to 
calculate the standard deviation. Each data point shown reflects n=3 or more from 2 or more 
batches of oocytes.  Statistics for comparison between different constructs were performed using 
independent t-test (Excel, Microsoft). The ± symbols in the text/table, and error bars in the 
figures represent the standard errors of mean (S.E.M.). 
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Chapter 3 
Predicting Patient Response to the 
Antiarrhythmic Mexiletine Based on Genetic 
Variation: Personalized Medicine for Long 
QT Syndrome 
 
3.1 Summary 
Background: Mutations in the SCN5A gene, encoding the α subunit of the Nav1.5 channel, 
cause a life-threatening form of cardiac arrhythmia, Long QT Syndrome Type 3 (LQT3). 
Mexiletine, which is structurally related to the Na+ channel-blocking anesthetic lidocaine, is used 
to treat LQT3 patients. However, the patient response is variable, depending on the genetic 
mutation in SCN5A.  
Objectives: The goal of this study is to understand the molecular basis of patients’ variable 
responses and build a predictive statistical model that can be utilized to personalize mexiletine 
treatment based on patient’s genetic variant.  
Methods: We monitored the cardiac Na+ channel voltage-sensing domain (VSD) conformational 
dynamics simultaneously with other gating properties for the LQT3 variants. To systematically 
identify the relationship between mexiletine block and channel biophysical properties, we used a 
system-based statistical modeling approach to connect the multivariate properties to patient 
phenotype.  
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Results: We found that mexiletine altered the conformation of the Domain-III VSD (DIII-VSD), 
which is the same VSD that many tested LQT3 mutations affect. Analysis of 15 LQT3 variants 
showed a strong correlation between the activation of the DIII-VSD and the strength of the 
inhibition of the channel by mexiletine. Based on this improved molecular-level understanding, 
we generated a systems-based model that successfully predicted the response of 7 out of 8 
patients to mexiletine in a blinded, retrospective clinical trial. 
Conclusions: Our results indicated that the modulated receptor theory of local anesthetic action, 
which confines local anesthetic binding effects to the channel pore, should be revised to include 
drug interaction with the DIII-VSD. Using an algorithm that incorporates this mode of action, we 
can predict patient-specific responses to mexiletine, improving therapeutic decision making. 
3.2 Introduction  
Class Ib antiarrhythmics are widely prescribed to treat patients with ventricular tachycardia, 
ventricular fibrillation(Priori, Blomström-Lundqvist, & Mazzanti, 2015), and Long QT (LQT) 
syndrome(Andrea Mazzanti et al., 2016). As a subset of the Class I agents that target the voltage-
gated cardiac Na+ channel, NaV1.5, Class Ib drugs preferentially inhibit the late component of the 
Na+ current (INa) to shorten action potential duration (APD) and prolong the effective refractory 
period (ERP)(Zipes & Jalife, 2013). Despite their ubiquitous clinical use, these drugs display 
high variability in efficacy and may cause a pro-arrhythmic response in some patients(Andrea 
Mazzanti et al., 2016; Ruan, Liu, Bloise, Napolitano, & Priori, 2007). For example, the classic 
Cardiac Arrhythmia Suppression Trial (CAST) showed that patients treated with NaV channel 
inhibitors encainide or flecainide (Class Ic) were 2-3 times more likely to experience adverse 
events, compared to patients prescribed a placebo(Echt et al., 1991). Reasons for this stunning 
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clinical failure include an inability to predict which patients will be effectively treated with Class 
Ib molecules.  
Recent clinical trials have shown that the class Ib drug mexiletine effectively shortens QT 
interval in a subset of LQT type 3 patients (LQT3)(A Mazzanti et al., 2016). LQT3 syndrome is 
caused by mutations in the SCN5A gene that encodes NaV1.5, and accounts for approximately 
10% of all LQT syndrome cases. Management of LQT3 has been challenging; beta-blockers, a 
mainstay of therapy for LQT1, have limited effectiveness for LQT3 patients and may be 
proarrhythmic(Shimizu & Antzelevitch, 2000). Despite mexiletine’s overall efficacy, a spectrum 
of QT shortening was observed in patients that carry different SCN5A variants, effects that were 
reflected in single cell electrophysiology recordings(Ruan et al., 2007). A precise understanding 
of how NaV1.5 mutations alter sensitivity to mexiletine would allow us to predict patient-specific 
response to mexiletine and develop better therapies.            
 
Mexiletine is typically prescribed to patients who respond to intravenously administered 
lidocaine in the clinic, and its advantage is that it can be taken orally. Due to the structural 
similarity between mexiletine and lidocaine, it has generally been expected that these molecules 
interact with the NaV channel via similar mechanisms. Mechanisms of lidocaine block have been 
studied for many years, and these reports show that it has a strong preference for the channels in 
the inactivated state(Bean, B.; Cohen, C J; Tsien, 1983; B Hille, 1977). This behavior is 
summarized by the modulated receptor theory proposed by Hille in 1977, which describes that 
the inhibitory action of local anesthetics is due to binding to a single receptor that is modulated 
by time and voltage dependent conformational changes within the channel such as those that 
cause inactivation(B Hille, 1977). Molecules may access this binding site in the channel pore 
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through both hydrophobic and hydrophilic pathways, where the hydrophilic pathway is only 
accessible when the pore opens, and the hydrophobic pathway through the cell membrane is 
accessible during both close and inactivated states of the channel (B Hille, 1977).  
Recent advances in the understanding of the molecular structure of the alpha-subunit of NaV 
sodium channels have shown that they are formed by a monomer with four homologous domains 
(DI-DIV), each composed by six transmembrane segments, S1-S6 (Gellens et al., 1992c). S1-S4 
of each domain form the voltage sensing domain (VSD), and S5-S6 form the pore. Upon cell 
membrane depolarization, the VSDs activate and open the pore and allows Na+ entry into the 
cell.  Based on the observation that the replacement of phenylalanine with Lysine at position 
1760 in the DIV-S6 segment eliminates use-dependent block by lidocaine (Hanck et al., 2009; D 
S Ragsdale, McPhee, Scheuer, & Catterall, 1996; David S Ragsdale, McPhee, Scheuer, & 
Catterall, 1994), it has been suggested that the drug binding site is within the pore region of the 
NaV1.5 alpha-subunit.  
More recent studies showed that VSD is part of the region that modulates binding of local-
anesthetics to Nav1.5. The observation was prompted by the observation that the pore and VSDs 
are tightly coupled and therefore conformational changes induced by the binding of drugs within 
the pore can affect the voltage and time dependence of VSD conformation. Experiments that 
monitor VSD activation have shown that when lidocaine binds to the channel, it stabilizes the 
DIII-VSD in an activated conformation (Arcisio-Miranda et al., 2010b; Sheets & Hanck, 2003). 
This phenomenon is thought to be caused by lidocaine holding the pore-forming DIII-S6 in a 
partially open conformation even under hyperpolarized potentials, which then allosterically 
modulates the DIII-VSD to predispose its activated conformation (Arcisio-Miranda et al., 
2010b).   
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We therefore hypothesized that the DIII-VSD plays an important role in the modulated receptor 
theory of local anesthetic block and it could contribute to the molecular mechanism underlying 
the heterogeneous response to mexiletine of different SCN5A variants that cause LQT3. Our 
results demonstrate the role of the DIII-VSD in the modulated receptor theory and create a 
systems-based model that predicts patient response to mexiletine therapy based on channel 
molecular gating properties.   
3.3 Results: 
Mexiletine stabilizes the active conformation of the DIII-VSD 
We examined the effect of mexiletine on heterologously expressed Nav1.5 channels. The 
response to mexiletine was similar for some properties and different for others of the class Ib 
antiarrhythmics. Like other class Ib antiarrhythmics, mexiletine preferentially inhibited the late 
component of the Na+ current (INa) compared with the effect on the peak current (D. W. Wang, 
Yazawa, Makita, George, & Bennett, 1997) (Fig 3.1A, top). Mexiletine also exhibited UDB (Fig 
3.1A, bottom), which is a property of class Ib antiarrhythmics that is reflected by an increase in 
the inhibitory effect as the channels are repetitively activated by depolarizing voltage pulses. 
Binding of class Ib drug lidocaine to the channel results in stabilization of the inactivated state, 
which is often reflected by a hyperpolarizing shift in the steady state inactivation (SSI) curve (D 
S Ragsdale et al., 1996). In contrast to lidocaine, mexiletine caused a minimal shift of the SSI 
curve (Fig 3.1B). However, similar to lidocaine, mexiletine delayed recovery from inactivation, 
especially the slow component of recovery (Fig 3.1C). Thus, mexiletine appeared to influence 
the inactivated state through a mechanism different from that of lidocaine.  
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Figure 3.1 Mexiletine blockade of NaV1.5 channel stabilize the DIII-VSD at the activated position.  
A. Representative current traces before and after 250 μM mexiletine tonic block (TB) and use-dependent block 
(UDB). B. Steady-state inactivation (SSI) curves before and after 2 mM mexiletine. Mexiletine induces minimal 
hyperpolarizing shift in SSI curve. C. Channel recovery from inactivation curves before and after 250 μM 
mexiletine. D. Left panels: Voltage dependence of steady-state fluorescence (F-V curves) from four domains (DI-
V215C, DII-S805C, DIII-M1296C, DIV-S1618C) before and after 4 mM mexiletine. Fluorescence after mexiletine 
was measured after 80% tonic block. Right panels: representative fluorescence traces before and after mexiletine. 
Mexiletine only affects DIII-VSD by causing a hyperpolarizing shift in DIII F-V curve and slows down DIII-VSD 
deactivation, without affecting other three domains. E. Proposed schematic (adapted from Arcisio-Miranda lidocaine 
model31) showing the mechanism of mexiletine stabilization of activated DIII-VSD. Only DI and DIII are shown 
and the VSDs are represented by a single S4 segment for clarity.   
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Previously, multiple studies demonstrated that lidocaine block of NaV channels enhances the 
stability of the DIII-VSD activated conformation (Arcisio-Miranda et al., 2010b; Sheets & 
Hanck, 2003). Here, we tested mexiletine interaction with the Nav1.5 VSDs by voltage-clamp 
fluorometry (VCF ) (Varga et al., 2015). In these experiments, a fluorophore is tethered to the 
charged S4 segment of one of the four VSDs.  As the VSD changes conformation, the 
environment around the fluorophore is altered, which changes emission from the fluorophore, 
enabling measurement of the time and voltage dependence of the VSD conformation. The 
steady-state fluorescence voltage (F-V) curves represent the voltage-dependence of the VSD 
activated conformation. Among four domains, only the DIII F-V curve displayed a large 
hyperpolarizing shift (ΔV1/2 = -32.5±7.5 mV, p = 0.04) after mexiletine block (Fig 3.1D), 
implying that the DIII-VSD remains in an activated conformation at more negative potentials 
upon mexiletine binding. Comparing the fluorescence traces before and after mexiletine block 
showed that both DIII and DIV-VSDs have slower activation and deactivation kinetics in the 
presence of mexiletine (Fig 3.1D). Because the DIII and DIV-VSDs are tightly coupled, the 
mexiletine-induced alteration of the DIV-VSD kinetics may be a consequence of its effects on 
the DIII-VSD. 
To account for mexiletine’s effects on the DIII-VSD, we proposed a model for its mechanism of 
action. Binding of mexiletine within the channel pore prevents the DIII-pore domain (S5-S6) 
from transitioning to a completely closed conformation during membrane repolarization (Fig 
3.1E). The partially open conformation of the DIII-pore causes the DIII-VSD to remain in the 
activated conformation. This is like previously reported mechanisms of the interaction of 
lidocaine with NaV channels.  
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LQT3 variants with different mexiletine sensitivities have distinct voltage dependence of 
DIII-VSD activation  
To understand the molecular mechanisms underlying differences in mexiletine sensitivity among 
LQT variants, we tested channels with single point mutations R1626P or M1652R (Fig 3.2A), 
which exhibit different responses to mexiletine4. These two variants exhibited different responses 
to mexiletine under nonstimulated conditions, tonic block (TB), and under stimulated conditions, 
use-dependent block (UDB). Consistent with the previous studies, when compared to the effect 
of mexiletine on WT channels, the drug exerted TB of R1626P at lower concentrations (EC50 = 
211.1 μM) and required higher concentrations to exert TB of M1652R (EC50 = 2035.3 μM). 
Mexiletine had an EC50=760.8 μM for TB of WT channels (Fig 3.2B).  
We assessed UDB by applying 400 ms depolarizing pulses at 2 Hz, mimicking conditions during 
ventricular tachycardia4. We found that WT and R1626P have comparable UDB (WT: 
EC50=58.4 μM, R1626P: EC50=56.6 μM), while M1652R has much lower UDB (EC50=192.7 
μM) (Fig 3.2C). We tested the UDB of mexiletine using the cut-open voltage clamp. The EC50 
values that we observed with this method are higher than those reported using patch clamp 
analysis of HEK 293 cells4. We hypothesized that this difference is due to limited solution access 
to the cell membrane in the cut-open voltage clamp set-up during perfusion. To test this 
hypothesis, we measured dose responses using two-electrode voltage clamp (TEVC), which 
allows better access to the solution. TEVC recordings showed mexiletine EC50 values for each 
variant that were similar to previously reported values (Table 3.1), suggesting that, in the cut-
open set-up, amount of mexiletine at the channel is approximately 3-fold lower than the perfused 
concentration (Table 3.1). With this information, we can account for the differences in EC50 
values that relate to methodology.   
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Figure 3.2 LQT variants with different sensitivities to mexiletine have distinct voltage dependence of DIII-
VSD activation. A. Topology of Nav1.5 channel and location of the two LQT mutations with distinct mexiletine 
sensitivity, R1626P (red ball, sensitive) and M1652R (green ball, insensitive). B. Concentration dependence of tonic 
block (TB) by mexiletine for WT, R1626P, and M1652R channels expressed in Xenopus oocytes. EC50 values were 
760.8 μM for WT, 2035.3 μM for M1652R, and 211.1 μM for R1626P channels. C. Concentration dependence of 
use-dependent block (UDB) by mexiletine. EC50 values were 58.4 μM for WT, 192.7 μM for M1652R, and 56.6 
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μM for R1626P channels. D. Voltage dependence of steady-state fluorescence of DIII. E.Steady-state inactivation 
(SSI) curves of WT, R1626P, and M1652R channels. F.Representative DIII fluorescence traces from WT-M1296C, 
M1652R-M1296C, and R1626P-M1296C. G.Proposed schematic showing possible mechanisms underlying the 
difference in mexiletine sensitivities between R1626P and M1652R. The DIII-VSD in the upward position 
represents the activated conformation. The lower position represents the inactivated conformation. At resting 
potential, R1626P has more activated DIII-VSD, which is coupled to the DIII pore domain (S5, S6), causing the 
pore to remain in a conformation with increase accessibility for mexiletine. In contrast, insensitive M1652R fewer 
activated DIII-VSDs, causing the DIII-pore to enter a conformation with less accessibility. H. The relationships 
between % of block and the fraction of DIII-VSD activated, or the fraction of current available for four different 
holding potentials (-120, -110, -100, -90 mV). I. TB by 500 μM mexiletine for F1760K, R1626P F1760K, M1652R 
F1760K channels.  
To probe the link between the DIII-VSD conformation and mexiletine block, we assessed the 
correlation between DIII-VSD conformation and sensitivity of the channel to mexiletine. We 
hypothesized that, if mexiletine block of the pore caused the DIII-VSD to remain in the activated 
position, then channels with an activated DIII-VSD conformation would facilitate mexiletine 
accessibility to the pore.  VCF experiments showed that both mutations significantly affected 
DIII-VSD conformation (Fig 3.2D, 2F), despite their locations in DIV-VSD, which is distant 
from DIII-VSD (Fig 3.2A). Compared to WT channels, the mexiletine-sensitive R1626P mutant 
exhibited a hyperpolarized DIII F-V curve (ΔV1/2 = -38.9 mV, p = 0.02), suggesting that more 
DIII-VSDs were in an activated conformation at the resting membrane potential. Conversely, the 
mexiletine-insensitive variant M1652R exhibited a depolarizing shift in the DIII F-V curve 
(ΔV1/2 = 28.2, p = 0.01), indicating that more DIII-VSDs were in deactivated conformation. The 
shifts in voltage dependence of the DIII-VSD activation mirrored the differences in block by 
mexiletine: The mutant with DIII-VSD in an activated conformation (R1626P) at the resting 
potential displayed higher TB. These results support our hypothesis of a reciprocal relationship 
between mexiletine block and DIII-VSD conformation of the mutants.     
Conventionally, occupancy of the inactivated state has been considered the primary determinant 
of class Ib drug action. Consequently, the modulated receptor model describes preferential drug 
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binding to channels that are inactivated. To test this notion, we measured how variants affected 
the SSI curve. Although the most sensitive mutation R1626P shifted SSI prominently, the 
magnitude of the shifts by these two variants are not consistent with their differences in 
mexiletine block (Fig 3.2E).  
 TB EC50 (μM) UBD EC50 (μM) 
cut-open voltage clamp 
 WT 760 58.4 
 R1626P 211 56.6 
 M1652R 2035 192.7 
    
two-electrode voltage clamp 
 WT 449.9 36.7 
 R1626P 86.3 18.5 
 M1652R 633.3 96.7 
    
patch clamp (HEK 293T) (reported in Ruan et al., 2007) 
 WT 253  38.0  
 R1626P 153  8.8  
 M1652R 944  96.1 
 
Table 3.1 Comparing EC50 for TB and UBD across different recording set-ups. Cut-open voltage clamp has 2 
to 3-fold higher EC50 compared to two-electrode voltage clamp and patch clamp due to obstructed access to 
solution during perfusion. 
To further test whether the conformation of DIII-VSD regulates mexiletine block independent of 
inactivation, we assessed TB of WT channels at various potentials ranging from -120 to -90 mV. 
At these holding potentials the WT channels exhibited full conductance (none in the inactivated 
state) (Fig 3.2E) and showed a range of DIII-VSD conformations (Fig 3.2D). At four different 
holding potentials, -120, -110, -100, and -90 mV, the channel showed altered TB by mexiletine 
(Fig 3.2H). Moreover, the amount of TB had a linear relationship with the fraction of DIII-VSDs 
in the activated conformation at those potentials (Fig 3.2H). This result showed that the 
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proportion of channels in the inactivated state is not the only factor that determines effectiveness 
of mexiletine block.  
Based on our results, we proposed a model that explains the difference in mexiletine sensitivity 
between the two LQT variants (Fig 3.2G). At resting membrane potential, DIII-VSD of the 
sensitive variant R1626P tends to occupy the activated conformation. Because the activated 
conformation of DIII-VSD is coupled to conformation of the DIII-pore, the pore adopts a 
conformation that facilitates mexiletine accessibility. In contrast, fewer of the DIII-VSDs of the 
insensitive mutant M1652R are in the activated conformation at these potentials, causing the 
DIII-pore to remain in a conformation that prevents mexiletine from binding.        
Voltage-dependent, not lipophilic, block accounts for differences in mexiletine response 
among LQT3 variants  
The F1760K mutation eliminates UDB by lidocaine and prevents lidocaine from affecting gating 
currents. Based on this binding site, Hanck et al. categorized lidocaine block into two 
components: a voltage-independent lipophilic block and a voltage-dependent block. Lipophilic 
block is independent of the putative binding site F1760. We tested whether the difference in the 
EC50 for TB by mexiletine among the R1626P, M1652R, and WT channels is due to lipophilic or 
voltage-dependent block by monitoring their responses to mexiletine in the background of 
F1760K mutation. 
We assessed the response of F1760K channels to mexiletine. Both TB and UDB by mexiletine 
are greatly reduced for the F1760K channel. Using VCF, we found that mexiletine did not alter 
the conformation of DIII-VSD of the F1760K mutant channel. We measured mexiletine-induced 
TB— at 500 µM, a concentration at which the difference in TB among the channels was evident 
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(Fig 3.2B), in WT, R1626P, and M1652R channels that also had the F1760K mutation. The TB 
achieved with 500 µM mexiletine in channels with F1760K was similar (Fig 3.2I). Thus, the 
differences in the EC50 values for mexiletine among these LQT variants appeared due to voltage-
dependent block rather than lipophilic block.  
Decoupling the DIII-VSD from the pore eliminates differences in mexiletine blockade 
among LQT3 variants  
To further understand how the DIII-VSD affects mexiletine block, we utilized the A1326W 
mutation (Fig 3.3A), which decouples DIII-VSD from the pore (Muroi et al., 2010). In channels 
with A1326W, mexiletine no longer affects the conformation of DIII-VSD, demonstrating that a 
connection between the DIII-VSD and the pore is required to observe the mexiletine effect on 
DIII-VSD conformation. Our hypothesis is that R1626P and M1652R have distinct mexiletine 
sensitivities due to differences in the voltage dependence of DIII-VSD activation, consequently 
altering pore accessibility by mexiletine. From this hypothesis, we predict that channels in which 
the DIII-pore is decoupled from the DIII-VSD by A1326W will exhibit similar mexiletine block. 
Indeed, we observed that, upon the addition of A1326W, mexiletine caused similar TB and UDB 
for the R1626P, M1652R, and WT channels (Fig 3.3B, C).  
In the presence of the A1326W mutation, the differences caused by R1626P or M1652R 
mutation in DIII-VSD activation and SSI are preserved (Fig 3.3D, E), suggesting that the 
A1326W mutation does not interfere with voltage-dependent DIII-VSD conformational changes. 
We proposed a model to explain the elimination of mexiletine sensitivity by the A1326W 
mutation in the two LQT3 variants (Fig 3.3F). Although R1626P stabilized and M1652R 
destabilized the activated conformation of DIII-VSD, the channel pore remains in the same 
conformation with the same mexiletine accessibility, because A1326W decoupled the DIII-pore  
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Figure 3.3 Mutation that decouples the DIII-VSD from DIII-pore eliminates differences in mexiletine 
sensitivity among LQT3 variants. A. Locations of the decoupling mutation A1326W and two LQT3 variant 
mutations, R1626P and M1652R. B. Concentration dependence of TB for A1326W, M1652R-A1326W, and 
R1626P-A1326W channels. EC50 values were 965.2 μM for WT, 1562.3 μM for M1652R, and 1440.7 μM for 
R1626P channels. C. Concentration dependence of UDB for M1652R-A1326W, and R1626P-A1326W channels. 
EC50 values were 113.0 μM for WT, 51.2 μM for M1652R, and 51.6 μM for R1626P channels. D. Voltage 
dependence of steady-state fluorescence of DIII for A1326W, M1652R-A1326W, and R1626P-A1326W channels. 
E. Steady-state inactivation (SSI) curves of WT, R1626P, and M1652R channels. The differences in SSI among 
different mutations are also preserved in presence of the A1326W background mutation. F. Proposed schematic 
showing a model of how A1326W eliminates the different sensitivities among LQT variants.   
from the DIII-VSD.  These results indicated that the differences in mexiletine sensitivity of 
R1626P and M1652R are a consequence of the effects of the mutations on DIII-VSD activation, 
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which are transmitted to the DIII-pore to increase accessibility to mexiletine. Thus, removing the 
coupling between the DIII-VSD and pore abolished the differences in mexiletine sensitivity.  
Voltage dependence of DIII-VSD activation determines mexiletine-induced tonic block 
(TB)  
By studying two LQT variants with extremely high or low mexiletine sensitivity, we showed that 
the voltage dependence of DIII-VSD activation strongly affects mexiletine block. We explored if 
this mechanism is generally applicable to common LQT3 variants. We first investigated how 
DIII-VSD activation modulates TB by mexiletine. TB is usually assessed at negative potentials (-
100 mV), a voltage at which most LQT variants have similar level of inactivation. DIII-VSD 
activation occurs at much lower voltage range than closed-state inactivation. Consequently, at -
100 mV, the variability in the proportion of channels with DIII-VSD in the activated 
conformation is high among LQT3 variants. We measured the gating properties of WT and 15 
LQT3 variant channels and the mexiletine TB of these channels. Most variants that we analyzed 
are found in patients who were previously treated with mexiletine. Even though the LQT variants 
span the channel (Fig 3.4A), many of the variants exhibited altered DIII-VSD activation. We 
observed a strong correlation between the voltage dependence of DIII-VSD activation (V1/2 of 
DIII F-V) and TB by (R2=0.90, Fig 3.4B).  Higher TB occurred for channels that had DIII-VSD 
activation at more negative potentials (Fig 3.4B). Instead of a linear relationship, we fitted the 
data to a Hill function, because we expected that TB will saturate at the ends of the curve. 
Intriguingly, we found that the minimum TB saturated at 15% block, suggesting that 15% of 
mexiletine-mediated TB is lipophilic block (low affinity, voltage-independent block).  
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Figure 3.4 Voltage dependence of DIII-VSD activation strongly correlates with tonic block by mexiletine. A. 
Locations along the primary sequence and channel topology of 15 LQT3 variants tested. B. Relationship between 
the voltage dependence of DIII-VSD activation (V1/2 of DIII F-V) and normalized tonic block by mexiletine. The 
data were fitted with a Boltzmann function and the correlation calculated. A strong correlation (R2=0.9) between 
these two parameters were observed when fitted with a Boltzmann function. C. Relationship between the SSI (V1/2 
of SSI) and normalized tonic block by mexiletine. The two parameters are not well-correlated, suggesting that 
channel inactivation is not a good predictor of mexiletine tonic block. 
We also investigated the relationship between SSI and TB to test the classical theory that closed-
state inactivation promotes class Ib block. In contrast to DIII-VSD activation, closed-state 
inactivation (V1/2 of SSI) did not correlate well with mexiletine TB (R
2=0.48, Fig 3.4C). These 
results further support the hypothesis that voltage dependence of DIII-VSD activation rather than 
that of closed-state inactivation determines mexiletine TB.  
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Partial least-square regression model predicts mexiletine use-dependent block and 
patients’ QTC shortening  
UDB is a critical feature of class Ib drugs, because this feature enables the drug to block 
channels during periods of heightened channel activity, as in tachycardia. Unlike TB, which 
occurs at resting potentials at which channels undergo limited conformational changes, UDB 
involves many complex gating transitions, including the activation of the other three VSDs, pore 
opening, pore closing, channel inactivation, and channel recovery from inactivation. Due to the 
complexity of the molecular movements that affect UDB, using a single gating parameter, such 
as SSI or DIII-VSD activation, to predict UDB is insufficient. To address this challenge, we 
applied a data-driven modeling approach to identify the multivariate relationship between 
channel gating parameters and UDB by mexiletine.  
For each LQT variant, we quantified 14 gating parameters that describe gating processes, such as 
DIII-VSD, DIV-VSD activation, channel activation, and channel fast inactivation (Fig 3.5A). 
We also assessed UDB by 250 μM mexiletine for each variant. To understand how these gating 
phenomena related to drug block, we utilized the partial least-square (PLS) regression approach. 
Gating parameters were used as predictive inputs, and the measured UDB was used as an output 
for the PLS regression model.  The PLS regression method has the ability to identify 
relationships between the measured gating parameters and UDB and can reduce redundancy 
amongst the input parameters.  
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Figure 3.5 Partial least square (PLS) regression model can predict UDB and QTc shortening by mexiletine 
from channel gating parameters. A. Left: heatmap of 14 quantified electrophysiological parameters (EP) of the 
gating for 15 LQT3 variants and WT channels with β1 or β3 subunits. Right: heatmap of each channel’s responses to 
mexiletine, including UDB and QTc shortening (ΔQTc) in LQT3 patients undergoing mexiletine treatment.  Bottom: 
VIP scores for each gating parameter. VIP scores were ranked by each parameter’s impact on model fitness. Each 
gating parameter is removed individually, and PLSR model was constructed with the rest of parameters. The 
corresponding model fitness was calculated based on Pearson correlation between measured block and predicted 
block with leave-one-out cross-validation. Higher VIP score (red) suggests that the gating parameter is more 
important for improving the model fitness. B-C. Relationship between measured and predicted UDB or ΔQTc. The 
predictions were made using the PLS regression model with parameters with high VIP scores. Model stability was 
tested with leave-one-out cross validation. 
We applied feature selection among the 14 gating parameters to identify the most important 
parameters in determining mexiletine UDB. Feature selection was based on the VIP (variable 
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importance in projection) score of each parameter (See Materials and Methods), which describes 
parameter impact on model fitness. Gating parameters with high VIP scores (Fig 3.5A bottom, 
red squares) were then extracted to build the final PLS regression model for prediction. The VIP 
scores suggest that 5 gating parameters are crucial for determining UDB, including voltage 
dependence of channel conductance (V1/2 of G-V), DIII-VSD activation (V1/2 of DIII F-V), DIV-
VSD activation (V1/2 of DIV F-V), time constant of slow recovery from inactivation (slow 
recovery τ), and late INa. By reducing the number of gating parameters used in the model, feature 
selection not only helps prevent overfitting but also improves our understanding of the 
relationship between channel gating processes and drug response.  
To reduce data dimensionality, we also decreased the number of principal components to 3, 
because 3 principal components were sufficient to explain 90% variants in our data. With the 
selected features and reduced components, the PLS regression model predicts the UDB with a R-
squared (R2) of 0.9. We further validated the model with “leave one out” cross-validation, as 
described in Methods. The cross-validated PLS regression model predicts the UDB with a Q-
squared (Q2) of 0.7 (Fig 3.5B). Compared to the best prediction using a single gating parameter 
(DIII-VSD activation), which has a Q2 of 0.3, the PLS regression approach improved the 
prediction accuracy.  
We also built a PLS regression model to predict mexiletine-induced corrected QTc shortening 
(ΔQTc) in patients with the LQT3 variants for which we measured channel gating parameters. 
We obtained QTc interval data before and after mexiletine for 32 patients with 13 different 
genetic variants from a previously published study6. The VIP scores for ΔQTc showed that only 
two gating parameters are important for determining the ΔQTc: DIII-VSD activation and τ of 
slow recovery from inactivation (Fig 3.5A bottom). With these two parameters as inputs, the 
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cross-validated PLS regression model predicted QTc shortening in patients with a Q-square (Q
2) 
of 0.6 (Fig 3.5C), demonstrating that the model has significant predictive value. Our results 
indicated that the clinical efficacy of mexiletine can be predicted from measurements of gating 
parameters of the NaV1.5 variants, supporting the proposal that in vitro testing may help predict a 
patient’s specific response to mexiletine4. We extended this observation by building a precise 
model for predicting patient specific QTc shortening by mexiletine based on detailed biophysical 
parameters.  
 
Figure 3.6 Test if gating parameter based on VIP scores can improve prediction by comparing with models 
generated with randomly selected gating parameters. A-B. Histogram of model fitness (R) for predicting UDB 
and ΔQT of 1000 PLSR models with 5 or 2 random selected parameters (blue) respectively. The fraction of models 
that contains 3 out of 5 (UDB) or 1 out of 2 (ΔQT) parameters with high VIP scores are shown in red. Those models 
have higher fitness than the rest of models, suggesting parameter selection based on VIP scores increases the model 
prediction accuracy. 
To validate if the gating parameters selected based on the VIP scores improved the prediction 
accuracy (model fitness) of the PLS regression models, we evaluated 1000 models with 
randomly selected parameters (blue bars, Fig 3.6). Among these models, those that contain most 
of the preselected parameters (more than 3 out of 5 for UDB and 1 out 2 for ΔQTc) had overall 
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improved prediction accuracy, implying that VIP score is an effective method to rank gating 
parameter importance.  
Finally, to facilitate utilization of our predictive model, we built a mexiletine QTc shortening 
calculator user interface (Fig 3.7). Users can select from a list of previously tested LQT3 variants 
or enter the channel gating parameters for a new variant, and then input the patient’s baseline 
QTc. The calculator will predict mexiletine shortening of QTc based on the PLS regression model 
and output patient’s predicted QTc after mexiletine therapy. If the patients’ predicted QTc after 
mexiletine is still above 500 ms (high-risk QTc
6), the warning light will illuminate, indicating 
that mexiletine is unlikely to be a sufficiently effective therapy in preventing arrhythmia events.  
 
Figure 3.7 Mexiletine QTc calculator: user-interface for the PLS regression model. Users can enter the patient’s 
baseline QT, select patient’s genetic variant or enter a new variant. The predict button runs the PLS regression 
model based on our training set data containing 13 LQT3 mutations. The calculator output the patient’s predicted 
QTc after mexiletine therapy. A red line that shows the predicted percentage of QTc shortening for the patient is 
displayed in the background of the histogram of all LQT3 variants in our database, which indicates the variant’s 
relative sensitivity to mexiletine 
 
69 
 
Test QTc shortening calculator performance with a blind clinical trial   
To test the accuracy of our ΔQTc predictions using the PLS regression model, we conducted a 
blind retrospective clinical trial that involved 8 LQT3 patients carrying 5 distinct SCN5A 
variants (Table 3.2, Fig 3.8), which were not variants included in the training dataset. The 8 
patients were previously treated with mexiletine and their electrocardiograms were recorded 
before and after treatment. Evaluators were blinded from these clinical data during prediction. 
We expressed the NaV1.5 channel variants from those patients and tested them in vitro to obtain 
the two essential electrophysiological parameters for the prediction: DIII-VSD activation and 
slow recovery τ. We generated the predicted post-mexiletine QTc is with the mexiletine QTc 
shortening calculator, with an upper and lower bound based on the 95% confidence interval 
calculated from the cross-validated model.  
Genetic 
Variants 
baseline 
QTc 
Measured 
post mex 
QTc 
Predicted 
post mex 
QTc 
Prediction 
lower 
bound 
Prediction 
upper 
bound 
F1473S 550 491 488 452 523 
I1768V 520 503 499 465 520 
K1500del 478 434 415 384 446 
K1500del 500 430 434 401 466 
K1500del 493 463 428 396 460 
K1500del 494 434 429 397 461 
L1608P 604 480 518 479 558 
N1774D 814 610 750 697 803 
 
Table 3.2 Mexiletine QTc calculator trial outcomes. 7 out of 8 patients have clinical measured QTc post 
mexiletine that fall into the predicted range.    
Strikingly, 7 out 8 patients had post-mexiletine QTc that aligned with our predictions (Table 3.2, 
Fig 3.8). We noted that the one outlier (N1774D) patient that we failed to predict had a baseline 
QTc of 814 ms, which is higher than most of the training data. Assembling patient data from 
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both training and trial datasets, we observed a trend that patients with very high QTc baselines (> 
650 ms) tend to have higher percentage of QTc shortening by mexiletine, independent of their 
genetic variants. As a result, our current model is not suitable for predicting patients with very 
high baseline QTc (> 650 ms). From this blind clinical trial, we validated that our PLS model 
accurately predicted patients’ response to mexiletine therapy for those patients with a baseline 
lower than 650 ms.  
 
Figure 3.8 PLS regression model predicts QTc shortening by mexiletine for genetic variants A. Locations of 5 
LQT3 variants that are included in the clinical trial and were not used for training the model. B. Comparison of the 
measured patients’ QTc after mexiletine therapy and the predicted QTc after mexiletine using the PLS regression 
model.   
We also tested the ability of PLS regression model to predict UDB with LQT3 variants that were 
not used for training the model. Using the critical gating parameters that we identified, the model 
accurately predicted UDB by mexiletine with Pearson correlation R of 0.82.      
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3.4 Discussion  
Mexiletine, as an oral Class Ib agent, is commonly prescribed to patients suffering from 
ventricular tachycardia (VT) and with a predisposition to sudden cardiac death, but who have a 
suboptimal response to β-blockers and the multitargeted antiarrhythmic amiodarone. Studies 
have shown that the efficacy of mexiletine is patient specific. However, the reason behind the 
patient specificity is poorly understood, resulting an inability to predict drug outcomes for a 
given patient. A better understanding of class Ib drug action is needed to develop precision 
medicine for management of ventricular tachycardia. A well-defined example of mexiletine’s 
variable efficacy is the LQT3 syndrome, an inherited arrhythmia syndrome caused by mutations 
in the SCN5A gene. Unlike other LQT syndromes, LQT3 patients usually experience episodes of 
ventricular tachycardia during rest and bradycardia (Ruan et al., 2007). Mexiletine is an effective 
therapy in suppressing arrhythmia events in some of these patients (A Mazzanti et al., 2016). 
However, patients carrying different SCN5A variants show varying QT interval shortening with 
mexiletine therapy, suggesting that the genetic variants perturb the channel in diverse ways to 
alter the mexiletine-channel interaction and thus drug efficacy.   
In this study, we investigated the molecular mechanism of drug action by determining how 
NaV1.5 mutations alter the sensitivity to mexiletine. We showed that DIII-VSD conformation is 
essential for determining mexiletine blockade. We propose a model where an activated DIII-
VSD causes the channel pore to remain in a partially open conformation that promotes 
mexiletine TB. Among the 15 common LQT3 variants tested, many variants altered the DIII-
VSD conformation, despite their distal locations to the DIII-VSD. We observed that mexiletine 
TB strongly correlated with the voltage dependence of DIII-VSD activation but not with SSI, 
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which further suggests that the DIII-VSD conformation rather than closed state inactivation of 
the channel controls the sensitivity to mexiletine TB.  
To predict patient-specific response to mexiletine, we used a systems biology approach, PLS 
regression. With data collected from 15 LQT3 variants and WT channels, we built a PLS model 
that accurately predicted mexiletine UDB and patients’ QTc shortening from measured channel 
gating parameters. Two gating processes, DIII-VSD activation and slow recovery from 
inactivation, greatly influenced both predictions, suggesting that they are important in 
modulating the dynamic interactions of mexiletine with the channel.  
An updated modulated receptor model describing Class Ib molecular drug action 
The modulated receptor theory proposed by Hille has been applied for 40 years to describe class 
Ib drug interaction with NaV channels (B Hille, 1977). This theory includes three basic and 
modulated channel states that illustrate drug interactions with the channel pore: closed, open, and 
inactivated.  The modulated receptor theory emphasizes the primary role of the inactivation gate 
in promoting and stabilizing drug blockade. As more information regarding channel structure has 
become available, it is apparent that many conformational changes that are spread throughout the 
channel work together to cause channel gating. The four VSDs exhibit varied behavior during 
gating, and each is coupled to the channel pore. Thus, subtle changes in VSD dynamics can 
affect pore conformation and vice versa.  
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Figure 3.9 Proposed updated modulated receptor model for class Ib antiarrhythmics. The model comprises 
five states, CR, CA, OA, IA, and IR. R and A represent the DIII-VSD at resting and activated positions, 
respectively. C, O, and I represent closed, open and inactivated states of the pore. Mexiletine has different binding 
affinity to each state. Thick red arrows represent high binding affinity, and the thin black arrows represent low 
binding affinity. After mexiletine blocks the pore, channels enter five drug modulated states, CR*, CA*, OA*, IA*, 
and IR*. The transition rates between modulated states change compared to those between the unmodulated states.  
This model provides a molecular basis for how mexiletine preferentially blocks the channel when the DIII-VSD is 
activated (CA, OA, IA). 
Previous studies showed that lidocaine binding to the pore affected DIII-VSD dynamics 
(Arcisio-Miranda et al., 2010b; Sheets & Hanck, 2003). We demonstrated that LQT3 variants 
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alter the voltage dependence of the DIII-VSD activation, and channels that populated an 
activated DIII-VSD conformation exhibit increased mexiletine block. To form a more complete 
understanding of channel and class Ib drug interactions, we considered various components of 
the channel. Based on these results, we propose an updated modulated receptor model that 
describes how conformations of the DIII-VSD, the pore, and the inactivation gate alter class Ib 
drug blockade. In this updated model, we included 5 states: CR (pore closed, DIII-VSD resting), 
CA (pore closed, DIII-VSD activated), OA (pore open, DIII-VSD activated), IA (pore 
inactivated, DIII-VSD activated), and IR (pore inactivated, DIII-VSD resting (Fig 3.9). Drugs 
can block the channel from each state, but with different binding and unbinding affinities. When 
channels are in the CR state, drugs have a low binding rate, because the hydrophilic pathway is 
unavailable. When the DIII-VSD activates, channels enter the CA state, in which drugs have 
much higher accessibility to the pore. Finally, in the channel open (OA) and inactivated (IA) 
states drugs exhibit very high binding rates. After membrane repolarization, channel recovery 
from inactivation has slower kinetics compare to the DIII-VSD deactivation, causing the channel 
to enter the IR state. Drugs have both low binding and unbinding rates when the channel 
occupies this state. When channels are in CR and IR states, only the hydrophobic pathway is 
accessible. 
Mexiletine interacts with the channel differently than lidocaine  
Due to the structural similarity between lidocaine and mexiletine, patients with ventricular 
tachycardia that respond well to intravenous lidocaine are often prescribed mexiletine for long-
term treatment. However, mexiletine fails to prevent arrhythmia in a large fraction (50%) of 
these patients (Zehender et al., 1988), and even induces severe arrhythmia in some cases (Cocco, 
Strozzi, Chu, & Pansini, 1980). This clinical outcome suggests that mexiletine and lidocaine 
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have distinct interactions with the channel that were not previously defined. Notably, mexiletine 
(pKa 9.52) is mostly hydrophilic, whereas lidocaine (pKa 7.6) is partly hydrophobic at 
physiological pH. Here, our results showed that the activated conformation of the DIII-VSD is 
required for hydrophilic drug, not for hydrophobic drugs, to access the channel pore. Many 
LQT3 variants stabilize the DIII-VSD in its activated position, promoting mexiletine block 
through the hydrophilic voltage-dependent pathway, which explains why mexiletine is effective 
in managing LQT3 syndrome. In contrast, for treating ventricular tachycardia patients with 
normal NaV1.5 channels that do not have activated DIII-VSDs, mexiletine may be less effective 
than lidocaine. These results suggest that response to lidocaine may not be a good predictor of 
the clinical response to mexiletine therapy.  
A better understanding of the drug mechanism suggests a novel therapeutic strategy  
We demonstrated several LQT3 variants are insensitive to mexiletine due to the less activated 
DIII-VSD conformation of the channel. To rescue their insensitivity, a new therapeutic strategy 
that uses a combination of drugs can potentially be employed. A drug that promotes DIII-VSD 
activation can be used in combination with mexiletine to improve antiarrhythmic efficacy in the 
insensitive variants. Several combination therapies of Na+ channel blockers have been tested in 
clinical settings (Duff, Mitchell, Manyari, & Wyse, 1987; Jordaens et al., 1990). For instance, an 
early study suggested that a combination of oral mexiletine and flecainide prevents recurrence of 
ventricular tachycardia in patients that are nonresponsive to monotherapy. From the present 
study, one may conjecture that flecainide may improve mexiletine efficacy by promoting DIII-
VSD activation. However, the mechanism of why certain combinations improve efficacy is not 
known. More work must be done to systematically evaluate how different combination therapies 
alter channel conformations and gating to improve drug outcomes.  
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For more general ventricular arrhythmias other than LQT3 syndrome, mexiletine is commonly 
prescribed to patients with recurrent ventricular tachycardia post myocardial infarction and 
ischemic heart diseases that are resistant to other conventional antiarrhythmic agents (H J Duff, 
Roden, Primm, Oates, & Woosley, 1983). Although mexiletine effectively suppress episodes of 
premature ventricular contraction (PVC), it induces adverse side effects in some patients 
resulting in them withdrawing from therapy (Group, 1984). Side effects include severe nausea 
and tremor. The incidence of side effects is dosage dependent. It is possible that higher doses are 
needed to suppress ventricular tachycardia in these patients, because they have wild-type NaV1.5 
channels, which are not as sensitive as some LQT variants. The patient-specific responses can be 
attributed to disparity in expression of NaV1.5 isoforms (polymorphisms) and accessory NaV β 
subunits(Yuan et al., 2014; Zhu et al., 2017). To reduce the side effects of mexiletine, the dose 
must be lowered while preserving its blocking efficiency. A combined antiarrhythmic therapy 
that promotes DIII-VSD activation could resolve this challenge.  
Understanding channel electrophysiology data with a systems biology approach 
Data-driven modeling is commonly applied in the field of systems biology, due to the large-scale 
nature of non-intuitive experimental data from biological assays, such as microarray and gene 
sequencing (Janes & Yaffe, 2006). Although the scale of data from channel electrophysiology 
recordings is much smaller, data-driven modeling can still be very useful, because ion channels 
themselves are complex systems, in which many parts of the channel work in concert to generate 
time- and voltage-dependent gating. Different voltage protocols can isolate different channel 
gating processes. Although effective, these voltage protocols are not ideal, because the properties 
they measure overlap.  For example, an inactivation change can affect protocols that measure 
activation by shutting down channels before the channels open maximally.  Statistical tools that 
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can reduce data dimensionality, such as principal component analysis and partial least square 
regression can reduce redundant information in data recorded with different voltage protocols.  
In addition to dimensionality reduction, the methods that we applied in this study has the 
advantage of recognizing the multivariate relationships between input (independent) and output 
(dependent) variables. It rotates the input data to new optimal dimensions that maximize the 
covariance between input and output data. Thus, PLS regression models can be trained with 
existing data, and then used to predict output of new input data. In this study, we built PLS 
regression models that predict mexiletine response using channel gating parameters. This 
approach can also be applied to predict other class I drug responses.  In the future, if a series of 
PLS regression models for common class I drugs is established, this series could be used to 
predict a patient’s response to available drugs. When a patient is identified with a new genetic 
variant, a patient’s response to various drugs could be predicted with the established PLS 
regression models. Moreover, a systems biology approach has the advantage of testing the 
outcomes of a combination of scenarios (Fitzgerald, Schoeberl, Nielsen, & Sorger, 2006). 
Different drug prediction models can be combined to discover an optimal therapy for a certain 
patient.   
Clinical perspective 
With our new findings of how channel gating dynamics determine mexiletine blockade, we built 
a PLS regression model that uses channel gating parameters to predict patient-specific response 
to mexiletine. We incorporated this regression model into a mexiletine QTc calculator that can 
output the patient’s predicted QTc after mexiletine therapy. The calculator gives users a warning 
if the patient is predicted to still have high-risk QTc (> 500ms) after therapy. In a blind clinical 
trial, we validated that the calculator accurately predicted the majority of patients’ post-
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mexiletine QTc. Overall, our understanding of the mexiletine molecular mechanism can be 
applied to predict patient-specific response to mexiletine, which can improve clinical outcomes 
of LQT3 management through a precision medicine approach.    
Study Limitations 
Since LQT3 is a rare disease and only a fraction of patients were treated with mexiletine, we 
have limited patient data for training the predictive model. The model performance can be 
improved as more patient data are added. In future studies, we hope to conduct a multicenter 
trial, to increase the sample size. We also noticed that our model underestimated mexiletine 
effects for patient with very long baseline QTc (> 650ms) in the clinical trial. However, it is 
important to consider that even though mexiletine reduces QTc in these patients, they still have 
high-risk QTc post therapy, suggesting it is necessary to apply mexiletine in conjunction with 
therapies, such as implantable cardioverter-defibrillator. 
Conclusions 
Mexiletine is widely used as an antiarrhythmic drug for patients with LQT syndrome and 
ventricular tachycardia. Patient-specific responses to mexiletine have been observed in clinical 
studies. However, the underlying mechanism is not well defined due to the lack of understanding 
of mexiletine’s molecular interactions with the NaV1.5 channel. We demonstrate that the 
conformation of the DIII-VSD of the NaV1.5 channel is crucial for determining mexiletine 
blockade. Using biophysical data and a systems biology approach, we built a model that can 
predict LQT3 patient QTc shortening with mexiletine therapy based on channel gating 
parameters. Our findings also suggest a new antiarrhythmic strategy of combination therapies 
that target molecular conformations of the channel to increase mexiletine efficacy.  
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3.5 Materials and Methods 
Molecular Biology 
cRNA for human Nav1.5 α subunit was produced from the pMAX vector. All mutagenesis was 
achieved using overlap extension PCR reaction, followed by In-fusion cloning (Clonetech). All 
mutations were confirmed with sequencing (Genewiz). Each plasmid was then linearized with 
PacI restriction enzyme. Capped mRNA was synthesized using the mMESSAGE mMACHINE 
T7 Transcription Kit (Life Technologies) and purified via phenol-chloroform extraction.   
Voltage Clamp Fluorometry  
Four previously developed constructs for VCF were used in recordings (DI: V215C, DII: S805C, 
DIII: M1296C, and DIV: S1618C). mRNA of the NaV1.5 channel constructs were co-injected 
with the NaV β1 subunit in Xenopus oocytes. Voltage clamp recordings were performed 4-5 
days after injection. The recording set-up, solutions, and recording protocols for VCF are the 
same as described previously16.  Mexiletine hydrochloride powder (Sigma) was dissolved in 
extracellular recording solution to a stock concentration of 4 mM. pH for the solution is adjusted 
to 7.4. Mexiletine was further diluted from the stock solution to various concentrations (2-1000 
μM). During recordings, measurements were made from the same cell before and after addition 
of the indicated concentration of mexiletine. Mexiletine was manually perfused into the 
extracellular solution chamber in the cut-open voltage clamp set-up.   
Electrophysiology Data Analysis  
Data analyses were performed with Clampfit (v10; Molecular Devices), MATLAB (R2012a; 
MATLAB), and Excel (Microsoft). G-V, fluorescence-voltage (F-V), and SSI curves were 
quantified by fitting a Boltzmann function: y=1/(1+exp⁡〖((V-V_(1/2))/k)〗. DIII-VSD 
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deactivation rate was quantified based on the time to 50% decay. Channel recovery from 
inactivation was fitted with a sum of exponents function: y=C-Af*exp⁡(-t/τf)-As*exp⁡(-t/τs), 
which accounts for both fast and slower components of recovery17. Comparison between 
conditions or constructs were performed using paired or independent student t test, respectively 
(Microsoft Excel). The error bars shown in the figures represent the standard errors of mean 
(SEM). 
Partial Least-Squares Regression  
Channel parameters (predictor variables) and channel responses to mexiletine (response 
variables) were standardized using z-score transformation. Partial least-square (PLS) regression 
was performed using MATLAB function “plsregress”. Model stability was examined with leave-
one-out cross validation. Each perturbation (channel variant) is individually removed from the 
dataset, and a PLS regression model is built on the rest of the variants. Using this model, 
mexiletine responses are predicted for the removed variant and compared with the measured 
responses. The model’s general ability to predict left-out data was measured by calculating the 
Q-squared (Q2) values, which is the sum of squares of the difference between predicted and real 
values, normalized by the total variability in data. Variable importance in the projection (VIP) 
scores for each gating parameter is ranked by its impact on model fitness (Q2). One gating 
parameter is removed at a time, and cross-validated model fitness Q2 is calculated for the model 
based on the rest of parameters. The lower the is, the higher VIP score the gating parameter has.  
Mexiletine QTc shortening calculator  
The final model containing all training dataset with reduced features for predicting QTc 
shortening (DIII-VSD activation and slow recovery τ) was implemented in a user-interface. 
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When the gating parameters for a new variant are entered into the calculator, they are normalized 
with the training dataset. The predicted percentage of QTc shortening is multiplied with patient’s 
baseline QTc for calculating predicted post-mexiletine QTc.   
Blind Retrospective Clinical Trial 
All predictions were made without prior knowledge of clinical outcomes. Predictions were made 
based on patient QTc baseline and their genetic variants. After measuring mutant channel gating 
properties, parameters were inputted into the mexiletine QTc shortening calculator, which then 
predicted post-mexiletine QTc intervals. The predicted values were then compared to clinical 
data.   
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Chapter 4  
Noncovalent β subunit modulation of 
interactions between NaV channel and Class 
Ib antiarrhythmics: a mechanism for 
chamber-specific response to drug therapy 
 
4.1 Summary 
The sodium channel β subunits form a macromolecular complex with the cardiac sodium channel 
(NaV1.5) to regulate channel expression and gating. In human hearts, β1 expresses at levels that 
are 3-fold higher in the atria compared to ventricles. Given that β subunits can modulate NaV1.5 
pharmacology, this differential expression could be exploited to target drugs to chamber-specific 
diseases (e.g. atrial fibrillation). 
We investigated how β1, through its interaction with the voltage-sensing domains (VSDs), 
differentially regulates NaV1.5 channel interaction with two commonly prescribed Class Ib 
drugs, lidocaine and ranolazine. Our results reveal that both lidocaine and ranolazine stabilize the 
Domain III VSD (DIII-VSD) in the activated position. However, in the presence of β1, the 
lidocaine DIII-VSD effect was enhanced, while ranolazine interaction was abolished. 
Consistently, use-dependent block by ranolazine was also impaired. To test whether this 
mechanism was operative in native myocytes, block by both drugs was measured in WT and β1 
(scn1b) knockout mouse ventricular myocytes. Consistent with our molecular observations, in β1 
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KO, lidocaine EC50 shows approximately 3-fold increase, while ranolazine EC50 was reduced 
to half compared to the WT. In vivo experiments show that IP injection of ranolazine prolongs 
PR interval and P wave duration in scn1b knockout mice, but not in WT mice, suggesting that β1 
expression reduces the ranolazine’s effect on peak INa in atria. 
We demonstrate that the β1 subunit differentially modulates lidocaine and ranolazine blockade of 
NaV1.5. The molecular mechanism underlying this phenomenon is due to altered drug 
interaction with the DIII-VSD. This molecular difference can be targeted to develop chamber 
specific antiarrhythmic therapies. 
4.2 Introduction  
Na+ currents (INa) carried by the NaV channels cause initiation and propagation of action 
potentials in atria and ventricles (Zipes & Jalife, 2013). NaV channels are formed by four 
homologous domains that are connected by intracellular linkers. Each domain contains six 
transmembrane segments (S1-S6). The S1-S4 form the voltage sensing domains (VSDs). VSDs 
undergo conformational changes upon membrane potential change, which then affects the pore 
(S5-S6) conformation, determining Na+ flux (Gellens et al., 1992b).  
NaV channels present in the cardiomyocytes as macromolecular complexes, which contain many 
regulatory and anchoring proteins that precisely control channel function and localization based 
on the cell type (Abriel, 2010). β subunits are essential members of this macromolecular 
complex. Five types of β subunits present in heart, β1, β1b, β2, β3, and β4. β1, β1b and β3 
interact with the channel non-covalently, while β2 and β4 modulates the channel by forming 
disulfide bonds (Calhoun & Isom, 2014). As β subunits play crucial roles in maintaining normal 
heart function, genetic mutations in β subunits have been shown to be associated with severe 
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arrhythmias, including Brugada syndrome, long QT syndrome, and sick sinus syndrome 
(Calhoun & Isom, 2014). β1 and β1b are the dominant isoforms in heart, as previous studies 
showed that their mRNA express at the highest level among all the β subunits.  
Although β subunits were first identified in the 90s, when they were co-immunoprecipitated with 
the NaV  channel from the cardiac tissue (Isom et al., 1992b), the molecular interactions between 
α-β subunits were not clear until recently. Recent cryo-EM structure of the eel NaV1.4-β1 
complex suggests that β1 co-assemble with the NaV1.4 around the domain III VSD (DIII-VSD) 
(Yan et al., 2017). Concurrently, optically tracking of the NaV VSDs using voltage clamp 
fluorometry (VCF) revealed that the β1 and β3 subunits differentially modulate the DIII and 
DIV-VSD movements (Zhu et al., 2017). Both structural and functional studies suggest that non-
covalently linked β subunits regulate channel function by interacting with the VSDs.  
The conformational changes of the VSDs are not only important for regulating channel gating, 
but also essential for modulating channel interactions with drugs, even for those that bind to the 
pore domain, such as local anesthetics (Muroi & Chanda, 2009a). Previously, VCF and gating 
currents recordings showed that when lidocaine blocks the channel, it stabilizes the DIII-VSD at 
its activated conformation (Arcisio-Miranda et al., 2010a). Moreover, in Chapter 3, we 
demonstrated that the alterations of DIII-VSD conformational changes by long QT syndrome 3 
variants, cause channels to have different sensitivities to Class Ib antiarrhythmic mexiletine.   
Class I antiarrhythmics modulate cardiomyocytes excitability through targeting the NaV 
channels. Class Ib drugs, such as lidocaine, ranolazine and mexiletine, specifically modulates the 
late component of INa, resulting in shortening of the action potential duration in ventricular 
cardiomyocytes (D S Ragsdale et al., 1996).  It was previously observed in expression systems 
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that β subunits could alter pharmacological responses of the NaV channel. However, the 
underlying mechanism and physiological impact of such alteration is poorly understood.  
In this study, we aim to understand the molecular mechanisms, whereby non-covalently bound β 
subunits modulate Class-Ib antiarrhythmics interaction with the NaV1.5 channel. We further 
investigated the physiological significance of this modulation by studying the scn1b knock-out 
mice.  
4.3 Results 
Both lidocaine and ranolazine alter the DIII-VSD conformation  
Previous work has shown that a local anesthetic, lidocaine, shifts the activation of the DIII-VSD 
in muscle isoform NaV1.4 to hyperpolarized potentials (Muroi and Chanda 2009; Arcisio-
Miranda et al. 2010; Hanck et al. 2009). Consistently, a class Ib antiarrhythmic mexiletine that 
shares similar structure as lidocaine also affects the DIII-VSD conformation upon binding. This 
interaction highly affects the use-dependence of the drug interaction (Hanck et al. 2009), and its 
alteration is therefore likely to have a significant therapeutic impact.  
Here, we tested two Class Ib antiarrhythmics, lidocaine and ranolazine’s (Fig 4.1A) effects on 
the DIII-VSD in the cardiac isoform NaV1.5 with VCF (Fig 4.1B). We observed a 
hyperpolarizing shift in the DIII F-V by 10mM lidocaine (ΔV1/2=-24.8±9.4 mV, p=0.03), and a 
similar shift by 2.5mM ranolazine (ΔV1/2=-30.7±7.5 mV, p=0.05), suggesting that both 
lidocaine and ranolazine stabilize the DIII-VSD in its activated conformation when bound to the 
channel. The similar effects on the DIII-VSD caused by both drugs are not surprising, since they 
share some common chemical functional groups. 
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Figure 5.1 Class Ib antiarrhythmics lidocaine and ranolazine stabilize the DIII-VSD to its activated 
conformation. A. Ranolazine is a derivative of lidocaine. They share similar chemical structure and common 
binding sites on the NaV1.5 channel. However, they modulate channel current differently in use-dependent manner. 
B. The conformational changes of the DIII-VSD is tracked by attaching a fluorophore to the DIII S3-S4 linker. C. 
When bound to the channel, both lidocaine and ranolazine cause hyperpolarizing shifts in the DIII F-V curves, 
suggesting a stabilization of the DIII-VSD at its activated conformation.   
 
β1 and β3 differentially modulates lidocaine and ranolazine’s interactions with the DIII-
VSD 
Recent cryo-EM structure of eukaryotic Na+ channel revealed that the β1 subunit is proximal to 
the DIII-VSD (Yan et al., 2017). We also showed previously that both β1 and β3 alter the DIII-
VSD dynamics during channel gating. Given that both structural and functional insights suggest 
that non-covalently bound β subunits modulate the DIII-VSD, we hypothesized that β subunit 
can also alter Class Ib antiarrhythmics’ interactions with the DIII-VSD. To test this hypothesis, 
we co-expressed NaV1.5 with the β1 or β3 subunit and measure the DIII-VSD conformational 
changes with or without lidocaine or ranolazine.  
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Figure 4.2 β1 and β3 differentially regulate lidocaine and ranolazine interactions with the DIII-VSD.  
A. Coexpressing NaV1.5 with β1 subunit enhances the DIII F-V shift by lidocaine but reduced the shift by 
ranolazine.  B. Coexpressing NaV1.5 with β3 subunit increases the DIII F-V shift by ranolazine but almost abolishes 
the shift by lidocaine.  C. Change in DIII F-V V1/2 after lidocaine or ranolazine application for α alone, α co-
expressed with β1 or β3. 
 
When we co-expressed the NaV1.5 channel with β1, we observed distinct DIII-VSD responses to 
lidocaine and ranolazine. Lidocaine block induced a greater hyperpolarizing shift in DIII-FV 
(ΔV1/2=-57.6±10.2 mV, p=0.01) (Fig 4.2A) when β1 was present, compared to the α subunit 
alone, while ranolazine block caused only a marginal DIII-FV shift (ΔV1/2=-12.8±16.8 mV, 
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p=0.53) (Fig 4.2A), suggesting that even when the channel pore is blocked by ranolazine, the 
DIII-VSD is still free to recover to its resting state, in contrast to the action of lidocaine. 
Co-expression with the WT β3 subunit caused an opposite effect on DIII-VSD. Upon lidocaine 
block, the DIII-FV was minimally shifted to hyperpolarized potentials (ΔV1/2=-25.3±10.9 mV, 
p=0.13) (Fig 4.2B), while the ranolazine effect on the DIII-VSD was potentiated, causing a 
larger hyperpolarizing shift in the DIII F-V (ΔV1/2=58.0±4.7 mV, p<0.001) (Fig 4.2B). 
Strikingly, even though ranolazine is a derivative of lidocaine and shares part of its chemical 
structure, expression of the β subunits differentially regulates the drug interaction with the DIII-
VSD (Fig 4.2C).  
Loss of β1 expression in mouse cardiomyocytes does not affect NaV channel gating  
To further investigated how non-covalent β subunits affects cardiomyocytes’ response to Class 
Ib antiarrhythmics, we utilized the cardiac specific scn1b Knockout (KO) mouse. First, we 
characterized the INa from ventricular cardiomyocytes acutely dissociated from the scn1b KO 
The peak INa is increased by 13% in scn1b KO cardiomyocyte compared to WT cardiomyocytes 
(scn1b KO: 81.3±3.6pA/pF, WT: 63.9±5.2pA/pF). A similar increase in peak current was also 
reported in the global scn1b KO. Other than the peak current amplitude, losing β1 expression in 
ventricular cardiomyocyte did not significantly alter other channel gating properties, including 
voltage dependence of activation (g-V) (Fig 4.3), steady-state inactivation (SSI) (Fig 4.3), and 
channel recovery from inactivation (Fig 4.3). This result is in contrary of previously reported 
β1’s modulation of INa recorded from heterologous expression systems, but consistent with 
results from global scn1b KO. Given that NaV channel form a macromolecular complex that 
involves many other regulatory proteins in cardiomyocytes, it is not unusual that losing one 
regulatory protein does not directly perturb channel function.    
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mouse heart.  
 
Figure 4.3 INa from scn1b KO and WT mouse cardiomyocytes have similar gating properties. A. 
Representative INa recorded from WT and scn1b KO mouse cardiomyocytes. B-C. loss of β1 in scn1b KO mouse 
cardiomyocytes did not affect channel GV, SSI, or recovery properties.  
 
INa exhibits increased block by ranolazine, but reduced block by lidocaine in scn1b KO 
mouse cardiomyocytes  
Even though loss of β1 in mouse cardiomyocyte does not significantly perturb NaV gating, we 
continued to investigate whether it still affects channels’ responses to the Class Ib drugs. We 
tested both lidocaine and ranolazine tonic block (TB) and use-dependent (UDB) of INa in WT 
and scn1b KO ventricular cardiomyocytes. Compared to WT, scn1b KO shows about 3-fold 
reduction in lidocaine UDB (WT: EC50=9.3uM, scn1b KO EC50=24.8uM), but significant 
increase in ranolazine UDB (WT: EC50=53.3uM, scn1b KO EC50=36.0uM) (Fig 4.4C, D). 
Ranolazine also exhibits more tonic block of INa in scn1b KO than WT (Fig 4.4B).  
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In mouse ventricular cardiomyocytes, we found that loss of β1 causes decreased lidocaine block, 
but increased ranolazine block. This result is consistent with our VCF data that suggest β1 
enhances lidocaine, but reduces ranolazine interactions with the DIII-VSD. The reduced effects 
on the DIII-VSD conformation could result in a lessened UDB.   
 
Figure 4.4 scn1b Knock-out show reduced lidocaine, but enhanced lidocaine response  
A.Tonic block (TB) of INa by 100uM lidocaine is slightly reduced in scn1b KO mouse cardiomyocytes, but not 
significantly B. Tonic block of INa by 100uM ranolazine is significantly enhanced in scn1b KO mouse 
cardiomyocytes. C. Use-dependent block (UDB) is measured by applying 8 repetitive depolarizing pulses of 400ms 
at 2Hz frequency, a protocol that mimics tachycardia. INa from WT mouse cardiomyocytes is more sensitive to 
lidocaine, compared to the scn1b KO. D. Opposite to lidocaine, INa from WT mouse cardiomyocyte is more 
sensitive to ranolazine, compared to the scn1b KO.    
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β1 differentially express in human atria and ventricles  
Since β1 alters Class Ib antiarrhythmics block of NaV channel, the expression level of β1 in 
cardiac tissue can play an important role in regulating drug responses. We quantified mRNA 
expression levels of all β isoforms in human heart tissue with RNA sequencing (Fig 4.5). We 
found that scn1b has the highest expression among all isoforms at the transcript level. Moreover, 
scn1b is expressed 3-fold more in atria compared to ventricles (Fig 4.5). In contrast, both scn2b 
and scn4b express significantly higher in ventricles compare to atria (Fig 4.5). This result shows 
that there is a chamber heterogeneity in β subunits expression.  
 
Figure 4.6 Scn1b has differential expression in human atria and ventricles. RNAseq data from human 
ventricular and atrial tissue. Scn1b has the highest expression among different β isoforms. The β1 expression at 
transcript level is ~3 fold higher in atria, compared to ventricles, suggesting a spatial heterogeneity of β1 regulation 
of NaV channel function in heart.   
 
Ranolazine and lidocaine induce distinct ECG phenotypes in WT and scn1b KO mice  
To further understand how β1 modulates antiarrhythmic responses at the whole heart level, we 
measured ECG for WT and scn1b KO mice before and after IP injections of lidocaine or 
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ranolazine (Fig 4.6). From the ECG measurements, we quantified several parameters that 
describe the heart electrical activities, including P wave interval (Fig 4.6) that represent atrial 
conduction, PR interval (Fig 4.6) that characterizes atrial-ventricular conduction, and QRS 
interval (Fig 4.6) that describes ventricle conduction. We found that both lidocaine and 
ranolazine significantly reduced the QRS interval for both WT and scn1b KO mice (Fig 4.6D), 
consistent with their function of reducing INa. Intriguingly, ranolazine significantly shortened the 
PR and P wave interval in the scn1b KO mice, but not in the WT mice (Fig 4.6B, C). This result 
suggests that loss of β1 enhances ranolazine’s inhibition of INa in atria.   
 
Figure 4.7 ECG recordings of WT and scn1b KO mice before and after lidocaine or ranolazine injection. A. 
Sample ECG recordings before and 20 minutes after IP ranolazine injection for scn1b KO mice. B-C. PR interval 
and P wave are significantly prolonged by ranolazine in scn1b KO mice, but not WT mice. 
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4.4 Discussion 
Although class Ib antiarrhythmics have great therapeutic potentials, they are not broadly used in 
clinics because of their proarrhythmic risks in some patients (Zimetbaum, 2012). Patient or 
disease variability of class Ib drug response suggests that there are external factors that modulate 
drug interactions with the channel (A Mazzanti et al., 2016). In this study, we investigated the 
role of Na+ channel accessory subunits β1 and β3 in regulating class Ib antiarrhythmics’ 
interaction with the channel. We demonstrated at a molecular level that expression of β1 and β3 
subunits differentially alter lidocaine and ranolazine’s effects on the DIII-VSD, where β1 
enhances lidocaine’s, but inhibit ranolazine’s interaction with the DIII-VSD. Conversely, β3 
eliminates lidocaine’s, but increases ranolazine’s effect on the DIII-VSD. This difference in 
molecular interactions between NaV1.5 DIII-VSD and class Ib antiarrhythmic drugs caused by β 
subunit result in distinct drug blockade of NaV channels in WT and scn1b KO cardiomyocytes.  
The β1 and β3 subunits alter NaV1.5 pharmacology via the DIII-VSD  
The DIII-VSD plays an important role in regulating channel gating. It is involved in both 
activation and inactivation processes(Albert Cha et al., 1999; Hsu et al., 2017a). However, it is 
not clear how DIII-VSD conformation modulates inactivation. Recent studies showed a 
correlation between DIII-VSD deactivation and slow component of recovery from inactivation, 
which suggest that an activated form DIII-VSD stabilizes inactivation. As Class Ib 
antiarrhythmics promote DIII-VSD to activate, it can subsequently increase the inactivation, 
which induce more UDB.  
Our results show that the presence of the β1 or β3 subunit can potently modulate the ability of 
Class 1b antiarrhythmics to stabilize of DIII-VSD in the activated conformation. This DIII-VSD 
effect of lidocaine has been previously shown to regulate use-dependent block, a critical feature 
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of Class-Ib drugs, which renders them most potent when myocytes are being excited repeatedly 
during an arrhythmic event. We observed that ranolazine and lidocaine similarly affect the 
Nav1.5 α subunit, when it is expressed on its own.  However, with the β1 subunit present, the 
lidocaine effect on the DIII-VSD was significantly enhanced, while the ranolazine effect was 
blunted.  Conversely, β3 enhanced ranolazine-induced DIII-VSD stabilization while inhibiting 
the lidocaine effect. Thus, despite the similarity of their chemical structures, the therapeutic 
response is drastically modified by the co-expression of the β1 and β3 subunits.   
Differential expressions of β1 in human atria and ventricle contributes to chamber-specific 
drug responses     
Ranolazine was proposed as a candidate for atrial specific therapy for atrial fibrillation 
(Burashnikov, Di Diego, Zygmunt, Belardinelli, & Antzelevitch, 2007; Zygmunt et al., 2011). 
Studies in canine heart illustrated that atrial and ventricular cardiomyocytes had distinct 
responses to ranolazine. In atria, ranolazine prolongs the APD90 and effective refractory period 
(ERP) (Burashnikov et al., 2007). In contrast, in ventricle, ranolazine shortens APD90. Here, we 
demonstrated a higher expression of β1 and β1b subunit in atria compared to ventricles. We also 
showed that β1 coexpression attenuated INa block. Notably, ranolazine is also blocker for HERG 
channel that conduct IKr, a repolarizing current (Antzelevitch, Burashnikov, Sicouri, & 
Belardinelli, 2011). If ranolazine’s blocking effect on INa is reduced in atria, its modulation of IKr 
current will dominant, resulting in prolongation of APD in atria. We think that the heterogeneous 
expression of β1 across different chambers is one of the underlying mechanisms for ranoalzine’s 
chamber-specific response.   
In this chapter, we demonstrated the role of non-covalently linked β subunits in regulating anti-
arrhythmic drug effects from molecular interactions to whole heart phenotypes.  
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Chapter 5 
Conclusions  
 
Heart diseases is the leading cause of death. Antiarrhythmic drug therapies were first used over 
100 years ago. However, the development of the field was discouraged by catastrophic failures 
of several early clinical trials. In the last decades, surgical procedure and devices had great 
success in treating arrhythmias. Nevertheless, those procedures are invasive and associated with 
high cost. Moreover, reoccurrence of arrhythmia after treatment is also fairly common for those 
procedures.  
In theory, the antiarrhythmia drugs that modulate different ion channels can directly target the 
fundamental pathologies of arrhythmia. Given the complexity of how different ionic currents 
interplay to control cardiac excitability, the antiarrhythmics need to precisely modulate channel 
functions temporally and spatially. When the Class I antiarrhythmics were first used in clinics, 
there was no information on the drug mechanisms, other than that they are NaV channel blockers. 
In the last few decades, great advances have been made in understanding the ion channel 
functions and structures, which are essential knowledge for understanding drug actions.   
We decided to revisit some of the antiarrhythmia drugs that were first used in the 70s. We aimed 
to probe the molecular interactions between NaV channel and Class Ib agents, and use that 
information to precisely guide Class Ib usage based on disease mechanism.  
As the NaV channels present in cardiomyocytes as macromolecular complexes, the drugs do not 
simply interact with channel alone. We first investigated how accessary β subunits modulate 
channel functions. We found that non-covalently linked β1 and β3 subunit alter the dynamics of 
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the DIII and DIV-VSD. Our functional results suggest that β1 and β3 reside on the opposite sides 
of the DIII-VSD.   
The DIII-VSD is also the domain that allosterically interacts with the Class Ib antiarrhythmics 
drugs. From studying over 20 LQT3 variants, we found that conformation of the DIII-VSD 
altered by different variant determines channel’s sensitivities to Class Ib drug mexiletine. 
Further, using this information, we build a system-based model that successfully predicted the 
LQT3 patients’ responses to mexiletine therapy in a retrospective blind clinical trial.   
We also wanted to understand the spatial heterogeneity of antiarrhythmic responses in heart. We 
studied how β subunits alter Class Ib interactions with the channel. We found that β1 and β3 
subunits have opposite effects on lidocaine and ranoalzine’s interaction with the DIII-VSD. This 
molecular difference resulted in different levels of block by these two compounds in WT and 
scn1b KO mouse cardiomyocytes. Since we also observed that β1 express 3-fold higher in the 
human atira,compared to the ventricles, we tested lidocaine and ranoalzine in vivo by injecting 
them in WT and scn1b KO mice. From measuring ECG before and after drug injection, we found 
that β1 specifically protect NaV channel from ranoalzine block in atria. The differential 
expression of β1 in different chamber can potentially be targeted for developing drugs for 
chamber specific diseases, such as atrial fibrillation.   
I believe that our studies are only the beginning of fully understand antiarrhythmic therapy from 
a molecular level. More future studies need to done in order to develop disease and patient 
specific therapeutic strategies with antiarrhythmics. I think the adverse effects by some drugs can 
be prevented with a complete understanding of drug mechanisms. Antiarrhythmic can eventually 
be beneficial for patients when we understand how to use them properly.     
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